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ABSTRACT 
As phosphorylation represents the pivotal mechanism for regulation of biological 
processes, kinases belong to one of the most biologically significant enzyme classes. The 
development of analytical techniques for characterization of kinase activity, in particular at a 
global scale, is a central priority for proteomic and cell biology researchers. In order to facilitate 
global analysis of cellular phosphorylation, a new paradigm of microarray technology which 
focuses on analysis of total cellular kinase activity, kinome, has emerged in the past few years. 
As the specificity of many kinases is dictated primarily by recognition of residues immediately 
surrounding the site of phosphorylation a logical methodology is to employ peptides 
representing these immediate sequences as experimental substrates. Microarray chips carrying 
hundreds of such substrate targets have been developed for human kinome analysis, however, 
lack of similar tools for species outside research mainstream has limited kinome analysis in 
these species. 
 Based on sequence alignment of orthologous phosphoproteins from mammalian 
species, conservation of amino acid identity is reported to be 80 %. Accordingly, the potential 
exists to utilize phosphorylation sequence databases to extrapolate phosphorylation sites in 
other species based on their genomic sequence information. Peptides representing these 
proposed phosphorylation sites can then be utilized as substrates to quantify the activity of the 
corresponding kinase. Based on these principles, a bovine microarray of 300 unique peptide 
targets was constructed. The bovine phosphorylation targets were selected to represent a 
spectrum of cellular events but with focus on processes related to innate immunity.  
Initial application and validation of the bovine peptide arrays was carried out for kinome 
analysis of bovine blood monocytes stimulated with either lipopolysaccharide (LPS) or CpG-
ODNs; ligands for Toll-like receptors (TLR) 4 and 9, respectively. The arrays confirmed 
activation of the known TLR signaling pathway as well as identifying receptor-specific 
phosphorylation events. Phosphorylation events not previously attributed to TLR activation 
were also identified and validated by independent bioassays. This investigation offers insight 
into the complexity of TLR signaling and more importantly verifies the potential to use 
bioinformatics approaches to create tools for species-specific kinome analysis based on 
genomic information.  
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1.0 LITERATURE REVIEW 
 
1.1 Kinases and Phosphorylation 
The reversible modification of proteins through the enzymatic addition of phosphoryl 
groups to the hydroxyls of specific amino acids such as tyrosine, serine and threonine is 
speculated to occur on up to half of the human proteome (Zhang et al., 2002). While the 
phosphohydroxyl linkages are chemically stable, they are readily reversed through the action of 
opposing phosphatase enzymes. The net phosphorylation status of the phosphoproteome, 
therefore, represents the collective influences of the protein kinases and phosphatases. 
An estimated 2% of the genes within the human genome code for either protein kinases 
or phosphatases (Hunter, 1995; Manning et al., 2002; Alonso et al., 2004). This corresponds to 
over 500 distinct kinases, only a fraction of which have been characterized with respect to their 
substrate targets and physiological functions. The frequency of protein phosphorylation is 
matched by its functional importance. Phosphorylation serves to regulate a variety of critical 
aspects of protein behavior including activity, stability, cellular localization and interacting 
partners. Regulation of protein function through phosphorylation is observed in virtually every 
cellular process including metabolism, cell division, apoptosis and signal transduction. As 
important players in signal transduction pathways, protein kinases play roles in transducing, 
amplifying or integrating upstream signals.  
There are two main groups of kinases: protein serine/threonine and tyrosine kinases. 
Such classification is based on the substrate specificity of kinases. Eukaryotic protein kinases 
belong to a single superfamily of protein kinases (ePKS) and within their catalytic domains, 
share extensive sequence and structural homologies. The kinase catalytic domain consists of 11 
subdomains (Hanks and Hunter, 1995) and is folded into a smaller N-terminal and a larger C-
terminal lobe. While the N-terminus is the ATP binding site and contains a glycine rich loop (P-
loop), the C-terminus is considered the activation lobe and consists of a conserved activation 
loop (T-loop) which is regulated by phosphorylation. A substrate binds to the cleft between the 
N and C-terminal lobes (Kobe et al., 2005). Human kinases, in addition to the catalytic domain, 
carry other functional domains. To date, 83 different domains have been reported in the human 
kinome (Krupa and Srinivasan, 2002; Manning et al., 2002). These domains are involved in 
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other aspects of kinase functions such as molecular interactions, localization and regulation. For 
example, Src homology 2 (SH2) and SH3 domains are two commonly encountered kinase 
domains (Manning et al., 2002). 
 
1.1.1 Kinase Specificity 
Cellular signaling accuracy and integrity depends highly on kinase specificity. Two 
critical elements determine kinase specificity:  1) Identity of phosphorylation target and 
residues around it and 2) recruitment of substrate. 
Binding of protein kinases to their substrates have been investigated through the 
analysis of the three-dimensional structures of protein kinases bound to peptide substrates. It is 
been reported that both classes of kinases bind their substrates in an extended conformation 
with the same orientation of the substrate peptide chain relative to the protein kinase (Hubbard 
et al., 1997; Brinkworth et al., 2003). Early investigations into the kinase specificity were 
focused on the importance of phosphorylation sites and residues around it (Tessmer et al., 
1977; Kemp et al., 1990) leading to the subsequent tabulation, compilation of databases and 
rationalization of phosphorylation motifs (Kreegipuu et al., 1998).   
The second factor that plays an important role in kinase specificity is recruitment of 
substrate by the kinase which plays a critical role in determining substrate preference. Substrate 
recruitment is any process that can bring a kinase and a substrate in close proximity, thus 
increasing the effective concentration of the substrate and the chance of forming the enzyme–
substrate complex. Some of the mechanisms of substrate recruitment inclue binding of the 
substrate to the regulatory domain of a kinase, or to a site distinct from the active site on the 
catalytic domain of the kinase (Lee et al., 2004); binding of the kinase and substrate to the same 
scaffolding protein (Faux and Scott, 1997); or co-localization of the enzyme and the substrate to 
a small subregion of the cell.  
 
1.2 Methods of Studying Phosphorylation 
While a variety of experimental approaches have been developed for analysis of cellular 
phosphorylation, they can be functionally divided into two categories, kinome and 
phosphoproteome analysis. The distinction is based upon whether the focus is on the protein 
kinases that mediate cellular phosphorylation events, the kinome, or the protein targets of these 
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enzymes, the phosphoproteome. While these terms are often used interchangeably, they 
represent distinct experimental approaches, albeit to the same biological phenomena.  
 The value of either kinome or phosphoproteome analysis is determined by the ability to 
accurately describe the underlying biology of cellular phosphorylation. Phosphoproteome and 
kinome investigations are generally comparative in nature with interest in characterizing 
differential patterns of phosphorylation in response to a particular stimulus or cellular event. 
Within this context there are a number of questions that are typically of interest: 1) Which 
proteins are phosphorylated and at what sites? 2) Under what conditions are particular proteins 
differentially phosphorylated? i.e under what conditions are the associated kinases activated? 3) 
Which kinases mediate these phosphorylation events? and 4) What are the functional 
consequences of phosphorylation both to individual proteins being modified as well as  to the 
overall cellular response?  There is no one analytical technique that can single-handedly address 
all these questions, but through the application of the complimentary approaches of 
phosphoproteome and kinome analysis a more comprehensive description of phosphorylation 
events is obtained. 
While the analytical capabilities for the description of the phosphorylation status of a 
single protein, or the quantification of the enzymatic activities of a single kinase, are becoming 
increasingly routine, the major challenge to both phosphoproteome and kinome analysis is for 
the development of capabilities for global characterization. This reflects a growing trend in 
biological investigations towards more systems approach to more fully appreciate the context 
and interplay of biological responses.  
 
1.2.1 Phosphoproteome Analysis 
The objective of phosphoproteome analysis is to define the members of this sub-
population of proteins and to identify their specific points of modification. While this shares 
many of the challenges associated with traditional proteomic analysis, it is experimentally 
complicated by the scarcity of many of the members of the phosphoproteome, the dynamic 
nature of this entity and the tendency of the remainder of the proteome to overwhelm, or 
actively suppress, detection of the phosphoproteome. 
One of the most significant challenges to phosphoproteome analysis is the low 
abundance of phosphoproteins relative to the proteome. This consists of two elements. Firstly, 
 4 
while a significant fraction of the proteins undergoes phosphorylation, many of these proteins, 
in particular those which are involved in signal transduction, are expressed at very low levels. 
Therefore the proteins that are of greatest interest are among the most poorly represented. This 
is exasperated by the fact that many of these low abundance proteins are phosphorylated in sub-
stoichiometric levels such that only a small fraction are modified at any given time. It is 
estimated that only 1-2% of the total amount of an individual member of the phosphoproteome 
is present in the phosphorylated form (Schlessinger, 1993; Mann et al., 2002; Kalume et al., 
2003; Raggiaschi et al., 2005). 
As a consequence of their low abundance, one of the central challenges and 
prerequisites for phosphoproteome analysis is the ability to discriminate these modified proteins 
from the remainder of the proteome. This can be achieved either through enrichment of 
phosphorylated proteins on the basis of the post-translational modification, prior to 
experimental analysis, or by separation of all the members of the proteome with subsequent 
phosphorylation-specific detection methods. In either strategy, the techniques employed need to 
be reproducible, specific for phosphorylation, but generally applicable to different types of 
phosphorylation. A number of experimental approaches have been employed to this end, most 
notably two-dimensional electrophoresis, antibody microarray and mass spectrometry. 
 
1.2.2 Kinome Analysis 
While the well-defined and highly conserved chemistry of phosphorylation reactions 
make it straightforward to characterize the enzymatic activity of an isolated kinase and its 
substrate, the challenge is in the application to global models. There are two primary obstacles 
to the development of a technology that permits global analysis of kinase activity. These are the 
creation of appropriate kinase substrates and the expansion of scale to permit simultaneously 
evaluation of hundreds of kinases to thousands of phosphorylation sites. Assays for the 
evaluation of the activity of a single kinase enzyme are relatively straight-forward provided an 
appropriate substrate molecule is available. The challenge of expansion of scale parallels those 
encountered in gene expression analysis in the transition from Northern blot analysis of selected 
genes to analysis of global patterns of gene expression. Not surprisingly, as array technology 
permits global analysis of gene expression, arrays have similar potential for investigations of 
protein-based biological events. 
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1.2.2.1 Peptides as Kinase Substrates 
For many protein kinases, recognition of phosphoacceptor substrates has been shown to 
be dependent on amino acid residues surrounding the site of phosphorylation rather than higher 
order tertiary structure effects (Kemp et al., 1975). Synthetic peptides modeled on the site of 
phosphorylation can be excellent kinase substrates with values of Vmax and Km approaching 
that of the natural substrate (Zetterqvist et al., 1976; Kemp et al., 1977). 
Utilization of such peptides has various advantages over complete protein sequences: 
they are easily synthesized and manipulated, are inexpensive to produce and highly stable. 
Preparation of arrays having hundreds to thousands of immobilized peptides offers an 
unprecedented opportunity for investigating the activities of hundreds of kinase enzymes and 
serve as valuable tools for profiling cellular activities. 
In some cases peptide substrates may not serve as ideal ligands for the corresponding 
protein kinase. There is the danger for the assignment of false positives as a result of 
phosphorylation of a particular peptide by a kinase other than the one that mediates cellular 
phosphorylation. For this reason it is important to verify kinomic results through alternative 
methodologies that permit direct characterization of phosphorylation status such as phospho-
specific Western blots. That the peptides are recognized by the correct protein kinase, but with 
lower efficiency than when the sequence is in the context of an intact protein, also presents the 
danger for false negatives where the activity of a kinase may be underestimated. For this reason 
it is difficult to make quantitative comparisons of the levels of activities of different kinases 
based upon the extents of phosphorylation of their corresponding peptides substrates. It is more 
appropriate to make comparison of the relative levels of activity of a particular kinase under 
different experimental conditions. 
 
1.2.2.2 Peptide Arrays for Kinome Analysis 
Array technology is being applied to monitor protein-based biomolecular interactions, 
including protein-substrate interactions (Blackburn and Hart, 2005), receptor-ligand 
interactions, antibody-antigen recognition (Kukar et al., 2002), determination enzymatic 
activities (Zhu et al., 2003), and specificities (Kim et al., 2005). Not surprisingly, it appears as 
though similar application of array technology will permit the advancement of kinome analysis. 
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One of the earliest applications of array technology for kinome analysis was screening the 
majority of kinases of yeast against a limited number of selected substrates. In this investigation 
full-length proteins were printed onto the arrays and evaluated for their ability to act as 
substrates for the yeast kinases (Zhu et al., 2000). While these arrays were simple relative to the 
total proteome, this was a pivotal study for demonstrating the potential for array technology to 
permit rapid screening of substrates for determination of kinase specificity.  
Synthetic peptide libraries have served as valuable tools for investigation of kinase 
specificity determinants (Till et al., 1994; Songyang et al., 1995). A critical outcome of these 
investigations was the demonstration of the ability for peptides, specifically in the context of 
arrays, to function as comparable ligands as the natural protein targets. Through the marriage of 
peptides as protein kinase substrates, and the application of array technology, it becomes 
feasible to construct an array that will permit large scale evaluation of the kinome. The 
potential for such an approach was first demonstrated by Houseman and Mrksich with an array 
constructed with peptides substrates to a non-receptor tyrosine kinase c-Src (Houseman and 
Mrksich, 2002). It was verified that this tool could be used to quantitatively evaluate kinase 
activity. Hence, in principle, an array exhibiting specific consensus sequences for protein 
kinases across the entire kinome would allow a comprehensive detection of signal transduction 
events in whole cell lysates. The application of peptide arrays for studying signal transduction 
events that are associated with specific stimuli or cellular events have been reported. One of the 
earliest reports involved generation of the first comprehensive description of the temporal 
kinetics of phosphorylation events induced by LPS. This methodology identified a novel kinase 
whose involvement in Toll-like signaling was not previously suspected and the results were 
confirmed through more traditional forms of analysis (Diks et al., 2004). Peptide arrays also 
proved a powerful tool for investigation of effects of glucocorticoid on insulin signaling 
pathways. An array with 1176 different kinase consensus substrates was employed to 
demonstrate inhibitions of the insulin receptor and several downstream signaling intermediates 
in response to glucocorticoid treatment. Importantly these effects were transcriptional-
independent and would have been undetectable by traditional genomic analysis (Lowenberg et 
al., 2005b). In a related investigating the application of the same peptide array was able to 
demonstrate that the immunosuppressive effects of glucocorticoids are mediated through the 
tyrosine kinases Lck and Fyn (Lowenberg et al., 2005a). 
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1.2.2.3 Detection of Peptide Array Signals 
A number of strategies are available for the detection and quantification of the 
incorporated phosphoryl groups to immobilized peptides. These include radiolabeling, 
fluorescent antibodies and chelators as well as surface plasmon resonance (Figure 1.1). 
 
Radioisotopes: When [γ-32/33P]-ATP is added to the kinase reaction mix, transfer of a 
radiolabeled phosphoryl group is catalyzed to a threonine, tyrosine or serine residue of the 
consensus sequences on the array (MacBeath and Schreiber, 2000; Falsey et al., 2001; Diks et 
al., 2004). Phosphorylation can be detected and quantified by exposing the array to a Phosphor 
Imager screen (Falsey et al., 2001; Diks et al., 2004). 
Care must be taken in employing [γ-32P]-ATP with peptides spotted on cellulose 
supports as the high peptide densities can create electrostatic traps for ATP, in particular with 
cationic peptides, creating false positives. Glass slides are more amenable to radioactive 
detection methods as their peptide density are approximately six orders of magnitude lower. 
Even though the usage of isotopes provides a very sensitive way to measure phosphorylation, 
due to the risk of handling and usage of radioactive material, researchers are turning to 
alternative techniques. 
 
Surface Plasmon Resonance Imaging: Surface plasmon resonance (SPR) imaging is a well 
established technique for studying molecular interactions (Rich and Myszka, 2000). However, 
it is still in its infancy for use with peptide array technology. An SPR biosensor characterizes 
interaction of molecules on a solid surface and a solution. The solid surface of a peptide array is 
required to be coated with gold or other noble metals (Wegner et al., 2002). As a proof-of-
concept Wegner et al. monitored interaction of peptides on a microarray with antibodies in 
solution (Wegner et al., 2002).  Inamori’s group established a new method: capturing 
phosphorylated residues of peptides with biotinylated zinc (II) complex and detecting them 
with streptavidin by SPR technique (Inamori et al., 2005). This detection method is 
independent of the amino acid residues so that detection all phosphorylated peptides on an array 
is possible using a single-probe complex. This system is quantitative for phosphorylation 
efficiency. 
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Figure 1.1. Summary of methods for detection of phosphorylated peptides. A) ATP labeled 
with an isotope such as 32/33P is added during the kinase reaction and phosphorylation is 
detected with a Phospho-Imager. B) Fluorescently labeled Phosphorylation-specific antibodies 
are added after the kinase reaction is complete, and phosphorylated peptides are detected by a 
fluorescence scanner. C) A labeled phosphoamino acid chelator is added after the kinase 
reaction is complete. Surface plasmon resonance, MALDI-TOF and MS is used for detection 
D) Phosphorylation-specific antibodies are added first to bind to phosphorylated residues and 
then fluorescently labeled antibodies are added to bind phosphorylation-specific antibodies. 
Adapted from Jalal 2007. 
 
 
 
C) D) 
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Fluorescence: This technique relies on fluorescently-labeled antibodies or chelators that bind 
to phosphorylated residues. Lesaicherre et al. were the first to develop this detection method 
(Lesaicherre et al., 2002). After the kinase reaction is completed, fluorescently-tagged 
antibodies are added onto the slide to bind the phosphorylated residues of the peptides. Binding 
of antibodies to the peptides is very sensitive; as little as femtomol antibodies of 
phosphorylated epitopes can be recognized by the antibodies (Lesaicherre et al., 2002). A 
fluorescence scanner is used to scan an image of the array. Unlike the radioisotope based 
technique, this method is safe and phosphorylation can be detected immediately after antibody 
binding. 
 The concerns associated with antibodies for detection of phosphorylation events parallel 
those presented with the application of phosphospecific antibodies in 2D-gels. A recent 
investigation examined the ability for phosphospecific antibodies to recognize their epitopes in 
the context of a peptide array. While monoclonal antibodies to phosphotyrosine residues 
demonstrated a high degree of specificity, antibodies for phosphoserine residues gave high rates 
of false positives and phosphothreonine antibodies showed concerning levels of cross-reactivity 
with the phosphoserine residues (Panse et al., 2004). 
 
1.2.2.3.1 Quantification of Kinome Activity 
While the extent of phosphorylation of a particular peptide is readily quantified, 
comparative analysis across different peptides is problematic as the ability for individual 
kinases to recognize and act on the appropriate sequences in the context of a peptide array will 
be unique for each kinase. Therefore while the absolute activities of the kinases cannot be 
determined, it is possible to report relative levels of activities of individual kinases under 
different physiological conditions.  
 
1.2.2.4 Peptide Array Design 
 
1.2.2.4.1 Knowledge-based Peptide Design 
Online databases such as Phosphosite (www.phosphosite.org) and Phosphobase 
(phospho.elm.eu.org) are compilations of experimentally reported and manually curated peptide 
substrates for human, mouse and rat kinases. In silico analysis of such online resources can 
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allow identification of substrates of interest. In silico analysis of the Phosphobase enabled 
identification of consensus amino acid phosphorylation sequences for most kinases present in 
the mammalian genome (Kreegipuu et al., 1999). 
For example, Diks et al. produced a peptide array, in which peptides were derived from 
in silico analysis of Phosphobase data. Their analyses revealed that peptides of nine amino 
acids in length could provide sensitive and specific binding to the kinases of interest. The 
nanomers were chemically synthesized and covalently immobilized onto glass slides. This array 
proved of considerable value in characterizing signal transduction events associated with 
activation of the Toll-like system (Diks et al., 2004).  
 
1.2.2.4.2 Bioinformatics for Sequence Determination 
Phosphobase and Phosphosite contain phosphorylation based data for well studied 
species such as human, rat and mouse. While such data are beneficial to researcher concerned 
with these species, not much data is available for other species. Our research group is interested 
in bovine kinomic analysis which requires a bovine-specific array.  
To obtain bovine-specific consensus sequences we relied on sequence comparison and 
homology to collect a list of consensus peptides for bovine kinases of interest. By first 
identifying human peptides from Phoshobase and Phosphosite and employing the Blastp 
program from National Center for Biotechnology Information(NCBI) to compare collected 
human peptides against the NCBI bovine protein database. Blastp was set to retrieve short exact 
matches.  
 
1.3 The Innate Immune System 
A pathogen’s detection and disposal, without damage to the host tissue, involves various 
mechanisms by the host immune system. Given the high molecular diversity of pathogens, and 
the frequent degree of mutations, the mammalian immune system has evolved mechanisms to 
meet such challenges. The mammalian immune system has been traditionally divided into two 
components: the innate and adaptive immunity (Hoffman et al., 1999). Adaptive immunity is 
responsible for specific responses and long-term memory of encountered immunological 
challenges while innate immunity responses have broader specificity and are generated within 
minutes to limit early invasion and spread of pathogens (Iwasaki and Medzhitov, 2004). 
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The adaptive immune response depends on two types of specialized immune cells, B 
and T lymphocytes. Each of these lymphocytes displays a structurally unique antigen receptor 
as a result of random gene rearrangements. The large repertoire of T and B receptors is highly 
diverse and it is extremely probable that one or more of these receptors will recognize an 
encountered antigen. Recognition of an antigen by the lymphocyte receptor triggers activation 
of the lymphocyte. To produce an efficient immune response, clonal expansion of the relevant 
lymphocytes is necessary. This typically takes 4-7 days, causing a delay in the immune 
response (Iwasaki and Medzhitov, 2004). Such a delayed response against rapidly replicating 
pathogens can be detrimental to the host. Hence the innate immune system is in place as the 
first line of defense against encountered pathogens. 
Innate immunity is considered the more evolutionarily ancient arm of the immune 
defense system. The same molecular modules of innate immunity are conserved across plants 
and animals indicating that the system existed before the split into these two kingdoms 
(Hoffman et al., 1999; Janeway and Medzhitov, 2002). From insects to large animals, the innate 
immune system serves as an indispensible component of the immune defense system.  While 
the vertebrates’ immune system consists of both innate and adaptive components, invertebrates 
lack adaptive immunity and rely entirely on the innate immunity (Medzhitov and Janeway, 
1997). 
An array of chemical, mechanical and cellular elements make up the innate immune 
system. First, the mechanical elements such as the epidermis and mucosa inhibit early 
penetration of pathogenic microorganisms. Binding of the pathogen to the host epithelium can 
trigger alarm signals resulting in the release of chemical elements such as chemokines and 
recruitment of other cellular elements, such as natural killer cells (NK), phagocytic cells, mast 
cells etc. These elements function in parallel to mount appropriate immune responses to rapidly 
eliminate infectious microorganisms. Major functions of the vertebrate innate immune system 
include: activation of the complement cascade and recruitment of immune cells to the site of 
infection, up-regulation of cytokines and chemokines expression resulting in inflammation, 
activation of immune cells to identify the pathogen and activate the adaptive immune system 
(Murray et al., 2002). 
Specific and appropriate engagement of the innate immune system is ensured by 
targeting highly conserved microbial molecules, pathogen-associated molecular patterns 
 12 
(PAMPs), which are produced by microbes but not by the host organism, such as bacterial 
lipopolysaccharide. Recognition and response to PAMPs is facilitated primarily through the 
pathogen recognition receptors (PRRs) (Gordon, 2002). PAMPs are invariant between microbes 
within the same class which allows recognition of a large group of the microbes by a single 
PRR. All PAMPs are essential for survival of the microorganisms making it difficult to produce 
mutated PAMPs which can escape recognition by the innate immunity (Ulevitch, 2004).   
 
1.3.1 Pattern Recognition Receptors (PRRs) 
Central to the innate immune recognition mechanism is a set of receptors appropriately 
termed PRRs. These germline encoded protein structures have evolved over time and have 
defined specificities for their ligands. A limited number of PRRs exist, although with a broad 
level of specificity, they can recognize many ligands which share a common molecular pattern 
such as DNA, RNA, and bacterial lipopolysaccharide. 
As the innate immune system recognizes infectious microorganisms in the early stages 
of an infection, these PRRs are expressed on cells that first encounter pathogens such as surface 
epithelium, antigen presenting cells (APCs), macrophages and dendritic cells (DCs) (Gordon, 
2002). In addition, a variety of other PRRs are expressed in intracellular compartments, or 
secreted into the bloodstream and tissue fluids (Janway and Medzhitov, 2002). PRRs are 
classified based on their cellular localization, target ligand group or function. For example, 
Toll-like receptors (TLRs) are the class of PRRs that are categorized based on their target 
ligands. 
 
1.4 The Toll-like Receptors 
The Toll-like nomenclature reflects similarity to Toll, a Drosophila melanogaster 
receptor essential in the establishment of dorsoventral polarity during embryogenesis, which 
was the first member of the Toll family to be identified (Hashimoto et al., 1988). Analysis of  
toll gene sequence revealed that it encoded a transmembrane protein with a Leucine-rich 
extracellular domain and a cytoplasmic domain that was similar to the cytoplasmic domain of 
the mammalian interleukin-1 receptor (IL-1R) (Gay and Keith, 1991). Moreover, it was 
discovered that D. melanogaster Toll was required for protection against fungal infection in the 
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adult fly (Lemaitre et al., 1996), as well as being involved in the Nuclear Factor kappaB (NF-
κB) signaling pathway similar to the mammalian IL-1R (Belvin and Anderson, 1996).  
A great deal of research has been directed towards discovering homologues of D. 
melanogaster Toll, referred to as Toll-like receptors (TLRs) in mammals (Medzhitov et al., 
1997; Rock et al., 1998). Human Toll-like receptor 4 (TLR4) was the first TLR recognized to 
activate the NF-κB signaling pathway similar to the D. melanogaster Toll. TLR4 was also 
reported to induce expression of cytokines and adaptive immune molecules through the NF-κB 
pathway (Medzhitov et al., 1997). Further studies in mice established that TLR4 acted as a 
receptor and signal transducer for bacterial lipopolysaccharide (LPS) to initiate innate immune 
responses (Poltorak et al., 1998; Hoshino et a., 1999; Qureshi et al., 1999).  
Mammalian TLRs belong to type I transmembrane proteins and are involved in 
recognition of a range of PAMPs (Janeway Jr. and Medzhitov, 2002). A wide variety of 
biomolecules have been identified which serve as TLR ligands, including microbial DNA for 
TLR9 (Krieg, 2002a) and LPS for TLR4 (Hoshino et al., 1999). Most of these ligands are 
conserved microbial products (PAMPs) that indicate the presence of an infectious agent. They 
share some common characteristics, although each mammalian TLR has a unique function. 
First, all TLRs recognize one or more structurally unrelated ligands. Second, some TLRs are 
known to require additional proteins in order to bind their target ligands. Finally, TLRs act as 
PRRs by recognizing PAMPs as well as prompting activation of the adaptive immune responses 
(Bowie and O’Neill, 2000; Takeshita et al., 2004).  
 
1.4.1 Members of the Toll-like Receptor Family 
To date, thirteen TLR family members have been discovered in mammals, including 11 
human, 12 mouse and 10 bovine homologues. Based on expression patterns and activation of 
cellular functions, TLR members show diversity among mammalian species. TLR1 through 9 
are conserved in humans, mice and bovine. TLR10 is expressed in humans and bovine, and a 
non-functional TLR10 has been detected in mice. TLR11 (also knows as TLR12) and TLR13 
are present in mice with a pseudo-gene for TLR11 found in humans (Leulier and Lemaitre, 
2008).  
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TLR1, TLR2, TLR6: These three TLR members belong to a subfamily based on their 
highly homologous amino acid sequences. Specifically at 66%, TLR1 and TLR6 have the 
highest amino acid sequence similarity among TLR family members and being located on the 
same chromosome, the two are thought to have duplicated from the same ancestral gene (Du et 
al., 2000; Takeda et al., 2003). Expression of TLR2 is seen on innate immune cells, as well as 
T and B cells (Lien et al., 1999; Borsutzky et al., 2005; Xu et al., 2005; Imanishi et al., 2007). 
Up-regulation of TLR2 is observed on mononuclear cells during influenza virus infection (Lee 
et al., 2006), chronic obstructive pulmonary disease (Pons et al., 2006) and sepsis (Harter et al., 
2004).  
TLR2 recognizes a repertoire of lipoproteins/lipopeptides (LP) that are present in the 
cell wall of various micro-organisms. For TLR2 to recognize such a broad range of LP 
molecules, it has developed the ability to form dimers with TLR1 or TLR6 which prompts its 
activation. Whether TLR2 binds with TLR1 or TLR6 is dependent on the length and 
arrangement of fatty acids of the LP (Ozinsky et al., 2000; Takeuchi et al., 2001; Takeuchi et 
al., 2002; Morr et al., 2002). Reports also indicate that TLR2 activation by some LPs is 
independent of TLR1 or TLR6 (Buwitt-Beckmann et al., 2005, 2006). 
  
TLR4: TLR4 was the first member of the TLR family to be identified. LPS from Gram 
negative bacteria is the best studied ligand for TLR4. However, evidence also suggests that 
several other PAMPs such as fusion protein from respiratory syncytial virus (RSV) and the 
envelope protein from mouse mammary tumor virus (MMTV) act as TLR4 ligands (Kurt-Jones 
et al., 2000, Rassa et al., 2002). In addition, host cellular molecules such as heat-shock proteins, 
hyaluronic acid and β-defensin 2 have also been reported to interact with TLR4 (Ohashi et al., 
2000; Biragyn et al., 2002; Termeer et al., 2002). 
The immunostimulatory responses induced by LPS include up-regulation of 
proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-6 and 
IL-1 (Akira, 2004). If hyperinflammatory responses are produced, tissue injury and damage to 
the host body can follow. Sepsis is the consequence of hyperactivity of TLR4 and is the leading 
cause of death in the intensive care units, causing approximately 200,000 deaths in the United 
States annually (Angus et al., 2001).  
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TLR5: Smith and colleagues were the first to identify bacterial flagellin as the agonist 
for TLR5 (Hayashi et al., 2001). Flagellin protein is abundantly expressed in flagella of Gram-
negative bacteria which is necessary for locomotion and survival of these micro-organisms 
(Macnab et al., 1992). In recent years, Smith’s group - through mutagenesis experiments- 
reported a 13 amino acid region of bacterial flagellin as the recognition site for TLR5. They 
discovered that the 13 amino acid cluster participated in intermolecular interactions within 
flagellar protofilaments and that were crucial for bacterial locomotion (Smith et al., 2003a). In 
contrast, the complementary interaction site on TLR5 was not identified until recently. Last 
year a new study by Smith’s research group identified that interaction between TLR5 and its 
agonist depended on the tertiary structure of the TLR5 (Andersen-Nissen et al., 2007). 
Furthermore, they refuted previously published work by two research groups who had claimed 
the interaction to be based on the primary sequence of TLR5 (Jacchieri et al., 2003; Mizel et 
al., 2003). Two conserved regions that are expressed on the surface regions of TLR5 
extracellular domain over a 228 amino acid span are reported as the interaction site between 
flagellin and TLR5. Binding of flagellin to a beta-sheet structure that is comprised of theses 
sites, activates TLR5 (Andersen-Nissen et al., 2007). 
 
TLR3, TLR7, TLR8, TLR9: These TLRs are grouped together as they are expressed 
in intracellular compartments as well as identify nucleic acid ligands. These TLRs specifically 
identify foreign nucleic acids due to two reasons. First, intracellular localization is suggested to 
provide cytoplasmic shielding from self nucleic acid and allow recognition of foreign nucleic 
acids. Endogenous nucleic acids do not enter the endosomal compartment, while pathogens 
commonly transit through this compartment (Akira, 2006). Second, vertebrate nucleic acids 
carry several modified nucleosides present in rRNA and tRNA or methylated nucleosides in 
DNA which inhibits binding by these TLRs (Krieg et al., 1995; Kariko et al., 2005). 
Nevertheless, some researchers have reported self DNA and RNA causing autoimmune 
responses (Krieg, 2002b; Leadbetter et al., 2002; Viglianti et al., 2003; Baccala et al., 2007).  
 
TLR3: By recognizing viral double-stranded RNA (dsRNA), TLR3 is reported to 
initiate immune responses and confer protection against some viral infections (Alexopoulou et 
al., 2001; Matsumoto et al., 2002). Moreover, it is established that particular sterically and 
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spatially organized synthetic dsRNAs can act as TLR3 agonists as observed with 
polyriboinosinic:polyribocytidylic acid (poly(I:C)) (a synthetic analogue of dsRNA). Activated 
TLR3 signals via the adaptor protein Toll-IL-1 receptor (TIR) domain containing adaptor 
molecule-1 (TICAM-1) which in turn activates transcription factors such as NF-kB and AP-1 
and leads to induced expression of Type I Interferon (IFN), inflammatory cytokine/chemokine 
production and myloid dendritic cell maturation (Oshiumi et al., 2003; Yamamoto et al., 
2003b). 
TLR3 is predominantly expressed in the endosomal compartment of immune cells such 
as myeloid DCs and in the endosomal compartments as well as cell surface of fibroblast and 
epithelial cells (Cario et al., 2000; Muzio et al., 2000; Visintin et al., 2001). Myloid DCs act as 
antigen presenting cells and activation of TLR3 in myloid DCs is suggested to generate 
adaptive immune responses, protection and memory against some viral infections (Heath, 
2004). The mechanism of dsRNA recognition by TLR3 is still not understood.  
 
TLR7/8: Single stranded RNA (ssRNA) from pathogenic viruses functions as ligand for 
TLR7/8 in humans as well as TLR7 in mouse (Heil et al., 2004; Forsbach et al., 2007; Hornung 
et al.,  2005; Melchjorsen et al., 2005; Diebold et al., 2006; Wang et al., 2006). Uracil or uracil 
and guanosine rich ssRNA found in untranslated genomic end regions of RNA viruses are 
suggested to act as physiological pathogenic ligands for TLR7/8(Heil et al., 2004; Forsbach et 
al., 2007; Hornung et al., 2005; Diebold et al., 2006). As uracil rich sequences are also present 
in eukaryotic RNA (Vollmer et al., 2005), it is unclear how TLR7/8 discriminates between self 
and foreign RNA. Although, some factors playing a role in such specificity of TLRs have been 
suggested such as the intracellular localization of TLR7/8 (Nishiya et al., 2004, 2005; Sioud et 
al., 2005) and the ability of cells to rapidly degrade unprotected self RNA in interstitial fluids 
by cellular RNAase allows discrimination of self from foreign RNA (Barton et al., 2006). 
Synthetic oligoribonucleotides (ORNs) containing guanosine and uracil complexed to 
liposomal or similar formulations have been shown to mimic pathogenic RNA effects and 
stimulate potent innate immune responses in vivo and in vivo (Diebold et al., 2004; Heil et al., 
2004; Scheel et al., 2004; Forsbach et al., 2007; Vollmer et al., 2005). Studies in mouse models 
demonstrate that such immune modulatory ORNs are efficient vaccine adjuvants and induce 
strong innate and adaptive immune responses (Scheel et al., 2004; Bourquin et al., 2007; 
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Hamm et al., 2007). Moreover, in cancer research some small molecular compounds, 
imidazoquinolines in particular, induce the antitumor activity of TLR7/8 (Gorden et al., 2005, 
2006; Jurk et al., 2006; Ma et al., 2007). While a few compounds are currently applied for 
topical treatment of skin cancer, others are still in clinical trials (Schon and Schon, 2008) 
 
TLR9: In the year 2000, TLR9 was cloned and identified as a receptor for bacterial and 
viral DNA rich in unmethylated cytosine-phosphate-guanine dinucleotides (CpG-DNA). TLR9 
has evolved to discriminate between the host and pathogenic DNA as CpG-DNA either appears 
at low frequency or is highly methylated in the vertebrate’s DNA (Hemmi et al., 2000). The 
phosphodiester backbone of the native DNA is the target of cellular nucleases and as such 
native CpG-DNA is rapidly degraded. To create a more stable CpG-DNA, synthetic CpG-DNA 
(CpG-ODN) with a phosphorothioate (PTO) backbone is utilized in TLR9 investigations. TLR9 
seems to be required for all immune stimulatory responses to synthetic PTO ODN which is 
supported by a complete loss of activity in mice genetically deficient for TLR9 (Hemmi et al., 
2000, 2003; Vollmer et al., 2004a). 
Expression patterns of TLR9 on immune cells differ among mammalian species. A 
limited number of cell types, B cells and plasmacytoid DCs (pDCs), and monocytes in humans 
express TLR9. Similar expression of TLR9 is also observed on bovine cells with the exception 
of monocytes (Griebel et al., 2005). In contrast, B cells, monocytes, and probably all DC 
subsets express TLR9 in mice (Iwasaki and Medzhitov, 2004). Consequently, TLR9 immune 
responses vary among different organisms making it unfeasible to extrapolate research 
conclusions across organisms.   
Both innate and adaptive responses are reported via TLR9 activation. For example, 
while conventional dendritic cells (cDCs) and macrophages produce proinflammatory cytokines 
such as IL-6, 1L-12 and TNF-α, pDCs secrete Type I IFNs which in turn activates cytotoxic T 
cells and helper T cells. Mature DCs activated through TLR9 induce T cells to mount adaptive 
immune responses (Hemmi et al., 2000, 2003; Liu, 2005; Havenar-Daughton et al., 2006). 
Although much data is available for TLR1 - TLR9 and TLR11 regarding their sequence, 
structure and biological significance, in comparison TLR10 - TLR13 have not been 
characterized to a significant level. For these TLRs their ligands, expression patterns and 
signaling pathways are not understood (West et al., 2006). 
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1.5 Structure of the Toll-like Receptors 
The TLRs are type I integral membrane glycoproteins with a high degree of structural 
conservation in particular in the N-terminal extracellular leucine-rich domain (LRR), a C-
terminal intracellular Toll/Interlukin-1 receptor (TIR) domain, and a transmembrane domain.  A 
TLR ligand interacts with the extracellular domain of TLR and intracellular signals are 
triggered via the transmembrane and TIR domains (Takeda et al., 2003). 
 
1.5.1 Extracellular Domain 
The ectodomains of TLRs are situated either outside the cell on the cell surface or in 
intracellular compartments. LRR motifs are a conserved feature of all TLR ectodomains. TLR 
ectodomains are comprised of 19-25 repeats of LRR motifs and each LRRs are comprised of 24 
amino acid residues. LRRs are categorized according to their primary sequences and 
conservation of amino acid residues. The consensus sequence for TLR-LRR is 
xL2xxL5xL7xxN10xφ12xxφ15xxxxF20xxL23x where x is any amino acid, L and F are occasionally 
replaced with other hydrophobic residues, φ is any hydrophobic amino acid and N10 is 
consistently replaced with C, S or T (Bell et al., 2003).  
Despite efforts by a number of research groups to resolve the crystal structures of TLRs, 
TLR3 is the only solved structure to date. The ectodomain of TLR3 structure reveals that 
individual LRR form a loop where the first 10 amino acids form a beta-strand and the 
remaining 14 a.a are an alpha-helix. A tertiary solenoid-structure results from the combination 
of the 23 LRRs. The conserved hydrophobic amino acids of each LRR form a tight 
hydrophobic core of the solenoid-structure. While the beta-strands occupy larger space than 
alpha-helices and give shape to a concave outer surface, the helices come together to form the 
convex center (Bell et al., 2005, Choe et al., 2005).    
Evidence based on the crystal structure of TLR3 suggests a direct interaction between 
the TLR3 ectodomain and its ligand (dsRNA) (Bell et al., 2005, Choe et al., 2005). The basis of 
an interaction between a TLR ectodomain and its ligand is suggested to be the LRR motifs. 
Such an interaction is also reported for human and mouse TLR1, TLR2, TLR4 and TLR5 
(Mizel et al., 2003; Andersen-Nissen et al., 2007; Jin et al., 2007), as well as murine TLR9 
(Cornelie et al., 2004; Rutz et al., 2004). Furthermore, other LRR containing proteins such as 
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NACHTLRR in vertebrates and NBS-LRR in plants have displayed similar properties (Kufer et 
al., 2005, Martinon et al., 2005).  
Two other conserved features among TLR ectodomains are the C- and N-caps. These 
non-LRR components are located at the C and N termini and flank the LRR regions similar to 
CD42b N-terminus cap. CD42b N-cap forms a β hairpin where disulfide bonds connect the β 
strands.  By covering the hydrophobic core of the first LRR motif, CD42b N-cap stabilizes the 
solenoid-structure (Huizinga et al., 2002). The C-cap structure unlike the N-cap has conserved 
sequence among TLRs as well as Drosophila Toll. Mutations introduced in the C-cap of 
Drosophila significantly reduced its activity and it is suggested that the C-cap plays an 
important role in maintaining Toll conformation (Schneider et al., 1991; Bell et al., 2003). 
 
1.5.2 TIR Domain 
Intracellularly the TLRs share considerable homology with the interleukin-1 receptors 
on the basis of a signaling domain known as the Toll interleukin-1 receptor (TIR) (Bowie and 
O’Neill, 2000). The primary sequence of TIR domains are composed of 135 to 160 amino 
acids. Conservation of three sequence regions referred to as Box 1, Box 2 and Box 3 has been 
identified in all TLRs. Box1 is unique to each TLR; Box 2 forms a loop referred to as “BB 
loop” which is essential in intracellular signaling activity; and Box 3 contains residues which 
are also essential for signaling (Xu et al., 2000). Mutations introduced in Box 2 of the tlr4 gene 
altered its ability to signal (Poltorak et al., 1998; Qureshi et al., 1999). Another important 
feature identified in the TIR domain is the “DD loop”. A recent investigation reported an 
interaction between the “DD loop” of TLR2 and the “BB loop” of TLR1 (Gautam et al., 2006). 
Such interaction is suggested to be the basis for TIR-TIR interaction between TLR-TIR 
domains and adaptor molecules containing TIR domains such as Myeloid differentiation 
primary response protein 88 (MyD88) (West et al., 2006).  
Through the resolution of TLR1 and TLR2 molecular structures, it is evident that the 
TIR domain is comprised of a central five-stranded, parallel β-sheet which is surrounded by a 
total of 5 α-helices on both sides. The core of the TIR domain starts at an (F/Y)DA amino acid 
motif and ends eight residues C-terminal to a conserved phenylalanine or tryptophan residue, 
and most of the conserved residues of the TIR domain lie within this hydrophobic core (Xu et 
al.,  2000).  
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The underlying cellular signaling events are initiated by the TIR domain. As the TIR 
domain is conserved across different TLRs in different species, it is proposed that similar 
signaling pathways are conserved across various species (Gay and Keith, 1991).  
 
1.6 Cellular Localization of Toll-like Receptor 
 Due to the conservation of structural components such as an LRR containing 
ectodomain, a transmembrane region and a TIR domain among all TLRs, it was initially 
hypothesized that all TLR family members were expressed on the cell surface. On the contrary, 
it has been established that while TLR1, -2, -4, -5 and -6 are expressed on the cell surface, 
TLR3, -7, and -9 are localized in the intracellular endosomal compartments. While TLR8 is 
often expressed on the cell surface, it is more frequently expressed intracellularly (Matsumoto 
et al., 2003; Funami et al., 2004; Nishiya and Defranco, 2004). 
 
1.6.1 Intracellular Members 
  
1.6.1.1 TLR9 and Oligodeoxynucleotide Ligand 
It has been known for more than two decades that bacterial DNA acts as a key 
immunostimulatory PAMP (Tokunaga et al., 1984). TLR9, now known as the receptor for 
bacterial DNA, was not discovered until 2000 (Hemmi et al., 2000). Through sequence 
comparison of previously discovered TLRs (TLRs 1-6) to expressed sequence tags (ESTs), 
Hemmi and his colleagues, discovered a high level of sequence similarity between an EST and 
selected TLRs. After retrieving a full-length complementary DNA sequence (cDNA), they were 
able to identify the conserved regions including TIR and extracellular domains on the newly 
discovered Tlr9 gene. Furthermore, they established that bacterial DNA carried unmethylated 
CpG motifs which were recognized by TLR9. This was evident from TLR9-deficient (TLR9
-/-) 
mice lacking immune responses to CpG DNA (Hemmi et al., 2000). Recent studies show that 
TLR9 recognizes viral-derived CpG DNA as well (Lund et al., 2003; Krug et al., 2004b). More 
specifically, activation of TLR9 on pDC cells by mouse cytomegalovirus (MCMV) (Krug et 
al., 2004a) herpes simplex virus (HSV) type 1 and type 2 (Lund et al., 2003; Krug et al., 
2004b) and adenovirus (Zhu et al., 2007) have been reported to  result in production of  IFNα 
and other cytokines. 
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Short single-stranded oligodeoxynucleotides containing CpG motifs (ODNs) can mimic 
the immunostimulatory actions of bacterial DNA. While bacterial DNA has a phosphodiester 
(PD) backbone which can be degraded quickly by cellular nucleases, ODNs have 
phosphorothioate modified (PTO) backbones with one or more non-bridging backbone oxygen 
atoms replaced with sulfur.  Optimally, ODNs are 8-30 bases in length with the most potent 
ODNs usually containing two or more CpG motifs (Krieg, 2002a). 
ODNs are classified into three subtypes on the basis of their unique immunostimulatory 
effects, backbone modification targets, and the number and positioning of CpG motifs (Krieg, 
2002a). Class-A ODNs, also known as D-type ODNs, are characterized by a phosphodiester 
backbone CpG motif and phosphorothioate-modified poly G stretches at the 5′ and 3′ ends 
(Krieg, 2006). These oligonucleotides elicit production of IFNα by pDCs which subsequently 
activates natural killer (NK) cells and induce IFNγ secretion (Hemmi et al., 2003). Class-B 
ODNs, also referred to as K-type, encompasses ODNs that are phosphorothioate-modified 
throughout their sequences, contain more than one CpG motif, and typically have linear 
conformations. Their immunostimulatory effects include DC maturation, B cell proliferation 
and activation resulting in high expression levels of Major Histocompatibility Class II complex 
(MHCII) (Klinman, 2004). Finally, the sequence for Class-C ODNs is structurally typified by 
complete phosphorothioate-modified backbone, multiple CpG motifs, and a 5’ TCG dimer. 
Class-C ODNs possess Class-A and Class-B immunostimulatory abilities such as activation of 
B cells and stimulation of IFNα production (Marshall et al., 2003).  
Some characteristics of ODNs, such as positioning of CpG motifs, formation of 
secondary structures such as hairpin structures, and residues flanking the CpG motifs are 
reported to dictate some of the immunostimulatory activity of the ODNs (Verthelyi et al., 
2001). Hairpin structures on the 5’ end of the ODNs greatly affect their immune stimulatory 
responses but to a lesser extent if located on the 3’ end. Given that the three classes of ODNs 
possess variable sequence properties, each class of ODNs can adopt a unique secondary 
structure. Although all ODNs can interact with TLR9, Class-specific responses may result from 
differential mechanisms of cellular localization, sequence/structure difference or unique 
costimulatory molecules. Species-specific responses to the ODNs are partially attributed to the 
residues flanking the CpG motif. For example, mouse TLR9 responds best to an ODN 
containing GACGTT motif because of the purine residues on the 5’ side and pyrimidine 
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residues on the 3’ side of the CpG. ODNs containing GTCGTT or TTCGTT are most effective 
with human TLR9 (Yu et al., 2003). Bovine TLR9 is reported to respond effectively to Class-B 
ODN 2007 (TCGTCGTTGTCGTTTTGTCGTT) where CpG motifs are flanked by one or more 
thymine residues (Nichani et al., 2006). 
 
1.6.2 Extracellular Members 
 
1.6.2.1 TLR4 and Lipopolysaccharide Ligand 
The first characterized mammalian Toll member was human TLR4. Currently 
expression of TLR4 is reported in a variety of cell types such as macrophages and DCs in 
humans, mouse, bovine, rabbit and other species. LPS is the structural component of the outer 
membrane of Gram-negative bacteria (Tobias et al., 1987). It is composed of a core 
oligosaccharide linked to an O-antigen, and lipid moieties referred to as lipid A (Raetz and 
Whitfield, 2002). Lipid A, or endotoxin, unlike other regions of LPS is recognized by TLR4 
and elicits innate immune responses.  
A high degree of diversity exists among lipid A structures of different Gram-negative 
bacteria. Common variations include: difference in the number and length of fatty acid side 
chains, as well as presence of terminal phosphate groups and modifications associate with them.  
Effective TLR4 recognition and immune responses to different lipid A structures is species 
specific. Reports indicate that maximal TLR4 stimulation of human cells occurs by hexa-
acylated E. coli lipid A with 12-14 carbons in length while modification introduced to the side 
chain reduced the magnitude of the signal (Schromm et al., 1998, 2000; Somerville et al., 
1999). Some reports also suggest that variations of lipid A from Helicobacter pylori (H. pylori), 
Legionella pneumophila ( L. pneumophila) are poor stimulators of human TLR4 (Girald et al., 
2003; Smith et al., 2003b). In comparison, mouse TLR4 can recognize a broad range of lipid A 
structures and mount protection against various human pathogenic bacteria such as E. coli, H. 
pylori and L. pneumophila (Kawasaki et al., 2000). 
Formation of a TLR4 complex with accessory molecules including LPS binding protein 
(LBP), CD14, MD-2 and TLR4 facilitates recognition of LPS by TLR4 (Gioannini and Weiss, 
2007; Miyake, 2007). Initially LBP, a soluble shuttle protein, directly binds LPS and converts 
oligomeric micelles of LPS to a monomer for delivery to CD14, which is a glycosyl 
phosphatidylinositol (GPI)-anchored, high-affinity membrane protein that can also circulate in a 
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soluble form. Association of LPS to CD14 allows transfer to TLR4/MD-2 receptor complex 
and positions LPS for recognition by the TLR4 receptor (Wright et al., 1989, 1990; Shimazu et 
al., 1999).  
 
1.7 TLR Signal Transduction 
The primary consequence of TLRs is expression and activation of immune molecules 
such as cytokines and chemokines, class II Major Histocompatibility complex and activation of 
transcription factors such as nuclear factor-kB (NF-κB) which shape the critical immunological 
response to counter pathogens. With the exception of TLR3, all TLRs signal through the 
universal adaptor molecule MyD88. Some TLRs recruit other adaptor molecules and trigger 
activation of receptor-specific pathways. This differential induction pattern depends heavily on 
cytoplasmic adaptor molecules that can associate with the intracellular region of the TLRs 
(Akira and Takeda, 2004). 
 
1.7.1 General TLR Signaling Pathway 
The majority of what is known about the TLR signaling pathways started with the 
discovery of the TLR adaptor molecule, MyD88. In 1994 Dan Hultmark suggested that MyD88 
was a transducer molecule, and together with IL-1R receptor, had ancestral function in 
activation of the immune system (Hultmark, 1994). Shortly after, Wesche and colleagues 
provided support for this hypothesis by showing that MyD88 interacted with both IL-1R-
associated kinase (IRAK) and the cytoplasmic domain of IL-1R mediating binding of IRAK to 
the receptor (Wesche et al., 1997). Given that there is a very high degree of similarity between 
IL-1R and TLRs, IL-1R research helped in understanding the details of TLR signaling 
pathways. In 1998, Medzhitov provided evidence that human TLR4 activated NF-κB by 
signaling through MyD88, IRAK-1 and TNF-receptor-associated factor 6 (TRAF6) (Medzhitov 
et al., 1998). Current research shows that MyD88 is the central adaptor molecule in the NF-κB 
signaling pathway that is commonly shared by all TLRs with the exception of TLR3 
(Alexopoulou et al., 2001). 
TLR signals are mediated through a central protein complex composed of MyD88, 
IRAK-1 and IRAK-4, and adaptor protein TRAF6 (Figure 1.2). Ligand binding to TLRs leads 
to formation of the protein complex as MyD88 recruits IRAK-4 and TRAF6 proteins.   
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Figure 1.2. A common signal transduction pathway shared by TLR family members. This 
pathway is initiated when a TLR ligand binds to its respective TLR receptor and induces TLR 
dimerization. The ligand-bound dimer then recruits MyD88 which in turn recruits IRAK-4. 
Another member of IRAK family, IRAK-1, is phosphorylated and activated by IRAK-4 and 
subsequently interacts with TRAF6. The TAB/TAK complex is recruited by TRAF6 and when 
activated, the complex triggers activation of the MAPK cascade. TAK also activates the IKKs, 
which phosphorylate IκB. Phosphorylated IκB dissociates from NF-κB and is degraded. NF-κB 
translocates to the nucleus to induce expression of NF-κB depended genes such as 
proinflammatory cytokines. In addition, two MAPK proteins, JNK1 and p38, activate 
transcription factor AP-1 which also translocates to the nucleus and activates expression of 
proinflammatory cytokines.   
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IRAK-1 is then phosphorylated by IRAK-4 and dissociates from MyD88, which results in 
TRAF6 activation. Subsequently, TRAF6 binds an ubiquitin ligase complex and activates 
mitogen-activated protein kinase kinase kinase (MAP3K or TAK1) in an ubiquitin-dependent 
manner. TAK1 acts as an activation node for NF-κB and the mitogen-activated protein kinase 
(MAPK) pathway which in turn activates extracellular signal-regulated kinase (ERK), and 
effector proteins c-Jun N-terminal kinase (JNK) and p38 MAPK kinase (Figure 1.2) (Kawai 
and Akira, 2007). 
The adaptor protein Myd88 is composed of a TIR domain that interacts with the TLR- 
TIR domains and a death domain (DD) that recruits IRAK proteins. Similarly, IRAK family 
members carry a DD domain that mainly interacts with Myd88 (Akira and Takeda, 2004; West 
et al., 2006). There are currently four known members of the IRAK family: IRAK-1, IRAK-2, 
IRAK-4 and IRAK-M. Whereas IRAK-1 and IRAK-4 are catalytically active, IRAK-2 and 
IRAK-M are inactive as a result of an absence of key residues in their respective kinase 
domains (Cao et al., 1996; Muzio et al., 1997; Li et al., 2002). 
Upon activation of TLR signaling, IRAK-1 and IRAK-4 are recruited to the receptor 
complex. At the receptor, IRAK-1 associates with MyD88, and TRAF6, and phosphorylation 
by IRAK-4 triggers IRAK-1 hyperphosphorylation and dissociation of IRAK-1 from the 
complex while still maintaining its engagement with TRAF6. IRAKs are subject to regulation 
at a number of levels including interaction with inhibitory molecules and inhibition of 
expression (Kawai and Akira, 2007). A number of these inhibitory molecules are well defined. 
For example, IRAK-M is an induced negative regulator that blocks IRAK-4 activation and 
subsequent IRAK-1 phosphorylation (Wesche et al., 1999).  
TRAF6 belongs to the TRAF family of proteins which is comprised of six members. 
The unique characteristic of these proteins is a novel TRAF domain at the C terminus which is 
essential for association with upstream receptors and other signaling molecules (Chung et al., 
2002). Each TRAF family member participates in distinct singaling pathways. TRAF6 is an 
essential signaling protein in TLR signaling pathways. Reports indicate participation of other 
TRAF members in TLR signaling pathways, however, in a regulatory manner (Wang et al., 
2006). 
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NF-κB transcription factor belongs to the Rel-homology domain-containing protein 
family and is comprised of homodimers and heterodimers of five related proteins: RelA (p65), 
NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelB and c-Rel (Kawai and Akira, 2007). Under 
normal cellular conditions, the inactive form of NF-κB is retained in the cytoplasm by an 
inhibitory molecule called inhibitor of κB (IκB). Upon TLR signaling through the MyD88, 
TAK1 leads to the activation of inhibitor of the κB kinase (IKK) complex which is composed 
of two catalytic (IKKα and IKKβ) and a regulatory (IKKγ or NEMO) subunits. IKK in turn 
phosphorylates IκB causing its degradation by the proteasome pathway, and allowing 
transcription factor NF-κB to translocate into the nuclei and regulate transcription of genes 
containing the κB regulatory elements (Kawai and Akira, 2007)..  
In order to prolong survival inside the host cells, pathogens have developed mechanisms 
to affect the NF-κB pathway. While a few pathogens, such as Shigella and Chlamydia, activate 
the NF-κB pathway to assist them in survival and replication by avoiding apoptosis of infected 
cells, most pathogens commonly inhibit the NF-κB pathway. For example, some bacteria insert 
toxins into the host cells to halt the NF-κB pathway by disrupting the MAP3K activation and 
subsequent activation and release of NF-κB by its inhibitor IκB. E. coli, Salmonella and the 
Measles virus have evolved ways to interfere with the degradation of IκB as well. A more 
interesting mechanism by Vaccinia virus involves expression of a MyD88 homolog by the virus 
to interfere with the binding of host MyD88 adaptor to TLR receptors and causing inhibition of 
NF-κB pathway (Wilson et al., 2002). 
 
1.7.2 Receptor-specific Pathways 
In addition to MyD88 adaptor, there are three other functional adaptors: Mal/TIRAP, 
Trif and Tram which interact with specific TLR receptors and initiate a number of different 
signaling networks in a MyD88-dependent or independent manner (Figure 1.3). Such TLR 
specific pathways present a mechanism by which the TLR system may tailor distinct responses 
for different types of pathogens.  
Some TLRs that signal through MyD88 activate a group of interferon regulatory factors 
(IRFs) leading to up-regulation of downstream immune response genes. IRF7, for example, was 
shown to participate in TLR7 and TLR9 signaling in a cell specific manner (Hochrein et al., 
2004; Honda et al., 2004; Kawai et al., 2004; Honda et al., 2005; Uematsu et al., 2005).  
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Figure 1.3. Receptor-specific signaling pathways. Some members of the TLR family 
participate in activation of IRF transcription factors through unique signaling pathways. 
Activation of IRF3 by TLR4 is achieved through recruitment of TRAM and TRIF adaptor 
molecules by TLR4 and interaction of these adaptor proteins with TBK1 and IKK kinases. 
Activation of IRF3 has not been reported by other TLR family members. TLR7, -8 and -9 as 
well as -4 activate other IRF members through interaction with MyD88 adaptor protein. After 
activation, IRF transcription factors translocate to the nucleus and regulate expression of 
immune genes such as type I IFN. 
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IRF5 is another transcription factor from the same family that is activated via MyD88 (Figure 
1.3). IRF5 has also been found in a complex with MyD88 and TRAF6 in TLR4 and TLR9 
signaling (Takaoka et al., 2005).  
Mal/TIRAP was discovered based on sequence similarity to MyD88. Mal and MyD88 
knock out mice responded in a similar manner to TLR4 signaling (Horng et al., 2002; 
Yamamoto et al., 2002a). Although both of these knocked out mice responded to TLR4 
agonists, their responses were delayed. During TLR4 signaling, Mal acts as a bridging adapter, 
enabling MyD88 to be a component of the TLR4 signaling complex, and MyD88 is the 
signaling adapter, leading to the downstream events. Mal is able to interact with Bruton’s 
tyrosine kinase (Btk) which phosphorylates Mal and facilitates its downstream signaling (Gray 
et al., 2006). Btk has been shown to participate in TLR2 and TLR4 signaling (Jefferies et al., 
2003; Liljeroos et al., 2007) through phosphorylation of NF-κB on its p65 subunit (Doyle et al., 
2005). However, the tyrosine phosphorylation of Mal is also required for its degradation 
providing a means to terminate its signaling (Mansell et al., 2006).  
One of the adaptors that were independent of MyD88 was discovered recently and was 
named TRIF (Yamamoto et al., 2002b; Hoebe et al., 2003; Oshiumi et al., 2003a). Role of TRIF 
in TLR4 signaling was established through TRIF-deficient mice. TLR4 requires TRAM to 
engage TRIF (Fitzgerald, et al., 2003b; Oshiumi et al., 2003b; Yamamoto et al., 2003b; 
McGettrick et al., 2006; Rowe et al., 2006). Thus, TRAM is also a bridging adapter like Mal 
and is different than all the other adapters in the fact that it is strictly utilized by TLR4.  TRIF 
signaling is amplified downstream by three molecules: an IKK-like kinase named the TRAF-
family-member-associated NF-κB activator (TANK)-binding kinase 1 (TBK1) (Fitzgerald et 
al., 2003a), the IKK homolog IKKε and IRF3. TRIF interacts with the three molecules resulting 
in phosphorylation and activation of IRF3 which subsequently acts as a transcription factor 
(Sato et al., 2003). Similar to IRF3, IRF7 becomes activated via its phosphorylation by TBK1 
and IKKε (Kawai et al., 2004; Honda et al., 2005; Uematsu et al., 2005). TLR4 also leads 
indirectly to NF-κB activation. This is happening via TRIF, which induces TNFα production 
through activation of IRF3. The TNFα is then secreted from the stimulated cells and binds to its 
receptor (TNFR) (Covert et al., 2005).  
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1.8 Levels of TLR Signaling Control 
 
1.8.1 Regulated TLR Expression on Different Cell Populations 
 
1.8.1.1 B Cells 
B cells are lymphocytes that arise from the bone marrow and act as APCs. A naïve B-
cell circulating in the blood or lymphatic sites recognizes, ingests and presents an antigen to an 
antigen-specific T-cell. The interaction between a B-cell and T-cell triggers proliferation and 
clonal-expansion of the B-cell leading to a humoral immune response. Recently, TLR-
dependant activation of B cells was reported to be required for eliciting humoral immune 
responses. Such an activation event leads to maturation of these cells and enables presentation 
of processed antigen to T cells in an immunogenic form. Mice carrying TLR deficient B cells 
lacked production of antibodies against protein antigens given with adjuvants (Pasare et al., 
2005).  Consistent with this observation, previous work had also suggested that murine B cells 
could be stimulated in vitro by TLR4 and TLR9 ligands to proliferate and secrete antibodies 
(Whitlock and Watson, 1979; Krieg et al., 1995). 
Through gene expression profiling of TLRs and measurement of co-stimulatory 
molecules corresponding to activation of TLR molecules, a new investigation has shown 
distinction between the TLR repertoires on murine and human B cells. Given that B cells are 
comprised of subsets, delving into details of TLR expression on each subset of human and mice 
is beyond the scope of this thesis. Suffice it to say that controversy exists regarding expression 
of TLRs on specific subsets of B cells (Oliver et al., 1997; Mansson et al., 2002; Bernasconi et 
al., 2003; Huggins et al., 2007) and details of expression of TLRs on all subsets is still not 
clear. Barr and colleagues suggest that in general murine B cells express TLR1-9. In contrast, 
other reports have shown that human B cells express TLR1-TLR10 with the exception of 
TLR3, TLR5 and TLR8 (Dasari et al., 2005; Barr et al., 2007).   
B cells produce cytokines similar to other APC populations such as DCs. The pattern of 
cytokine expression by B cells is dependent on the activation of a particular subset of B cells. 
Barr and colleagues investigated the pattern of cytokine expression by DCs and B cells. Their 
report indicates distinct response patterns from different APC populations stimulated via the 
same TLR.  B cells make IL-10 and IL-6 following TLR4 and 9 ligation, in contrast to DCs 
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which produce IL-12, IL-6 and IL-10. In addition, IL-6 is elicited in B cells via TLR2, 4 and 9, 
but through TLR3, 4 and 9 in DCs (Barr et al., 2007). This suggests that the composition of the 
membrane-proximal TLR signalling elements (adaptors) differs between these two important 
APC populations. 
 
1.8.1.2 Monocytes 
Monocytes originate from progenitor cells of the bone marrow and are mononuclear 
phagocytes circulating in blood. Once a monocyte exits blood, it differentiates into a 
macrophage or DC (Chomarat et al., 2003), and the cell is no longer referred to as a monocyte, 
but rather as a monocyte-derived cell. Overall, monocytes are defined as cells that (a) are 
mononuclear and circulate in blood (b) have phagocytosis capabilities and (c) maintain some 
repertoires of macrophages and monocyte-derived DCs (Chomarat et al., 2003).  
Two main subsets of monocytes have been identified in mice and humans. Assignment 
of monocytes to a subset is on the basis of the expression of surface markers such as 
chemokines receptors and adhesion molecules. A subset of monocytes in mice is referred to as 
inflammatory monocytes, express chemokines receptor CCR2, cell surface protein Ly6c (Gr1+), 
and adhesion molecule L-selectin. Their names rather reflect their recruitment to sites of 
inflamed tissues and lymph nodes (Geissmann et al., 2003). By differentiating to inflammatory 
DCs, these monocytes replenish repertoires of these cells in skin, digestive tract and lung 
(Varol et al., 2004; Ginhoux et al., 2006). The second subset of murine monocytes referred to 
as resident monocytes are recruited to both inflamed and resting tissues. They lack markers 
unique to inflammatory monocytes and instead express chemokine receptor CX3CR1 and LFA-
1 integrin (Geissmann et al., 2003). Human monocytes are divided into CD14+ CD16– and 
CD14low CD16+ subsets. While CD14+ CD16– monocytes resemble murine inflammatory 
monocytes, CD14low CD16+ monocytes are similar to murine resident monocytes (Geismann et 
al., 2003). In comparison to human and mouse monocytes, bovine monocytes are not 
characterized extensively; however, reports confirm expression of CD14+ and L-selectin on 
bovine blood monocytes (Wang et al., 1997; Eun et al., 2004). 
Monocytes have the ability to quickly recognize pathogens, mediate phagocytosis and 
respond with the production of reactive oxygen and nitrogen species, antimicrobial peptides, 
and inflammatory mediators (Medzhitov et al., 2000). Such important immune functions are 
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initiated by TLR modulation of signaling pathways. Human monocytes are reported to express 
TLR 1, 2, 4, 5, 8 and 9 (Hornung et al., 2002; O’Mahony et al., 2008)  
 
1.8.1.3 Dendritic Cells 
Dendritic cells (DCs) are APCs and originate from the bone marrow. Their ability to 
recognize an extensive range of antigens and their presence in virtually all tissues interfacing 
the host and environment make them the most important APCs. DCs are broadly categorized 
into two subsets: myeloid (mDCs) and plasmacytoid (pDCs). In human, these subsets of DCs 
express a variety of TLRs. Myloid DCs reportedly express the complete repertoire of TLRs 
while plasmacytoid DCs express limited number of TLRs such as TLR7 and TLR9 (Muzio et 
al., 2000; Seya et al., 2005). The in vivo requirement of DCs to initiate immune responses to 
specific TLR agonists is not fully understood. 
 
1.8.2 Phosphorylation-Mediated Signal Transduction in TLR Activation 
Proteins comprising TLR signaling adaptor molecules, kinases and effectors are 
regulated through various post-translation modifications including phosphorylation, 
ubiquitination, acetylation, sumoylation and nitrosylation (Perkin, 2006). The degree and type 
of modification can vary, depending on the nature of the TLR-inducing stimulus. Moreover, 
such modifications frequently have distinct, sometimes antagonistic, functional consequences 
and the same modification can have different effects depending on the context.  
Phosphorylation serves as an important regulatory mechanism for the TLR signaling 
pathways. Critical aspects of a protein function such as activity, stability, cellular localization 
and interacting partners are regulated through this post-translation modification. 
Phosphorylation of adaptor molecules, MyD88, Trif, TRAM as well as transcription factors 
such as NF-kB, IRFs, c-Jun, p38, and activity of IKK and MAPK family of kinases comprise 
essential signaling molecules of TLR pathways (Miggin and O’Neill, 2006; Perkin, 2006). 
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2.0 HYPOTHESIS AND OBJECTIVES 
Comparison of short amino acid sequences representing human phosphorylation targets 
to a bovine protein database will identify bovine orthologues. These bovine peptides can be 
used to create a bovine-specific array for kinome analysis of bovine cells. 
 
Objectives: 
1. Identify bovine phosphorylation targets and create a bovine peptide array. 
2. Test new peptide arrays by performing kinome analysis on bovine 
monocytes treated with TLR agonists. 
3. Verify kinome analysis with bioassays. 
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3.0 MATERIALS AND METHODS 
 
3.1 Reagents and Chemicals 
All chemical reagents required to carry out experiments throughout this thesis are listed 
in Table 3.1. 
 
3.2 Bovine Peptide Array Development 
 
3.2.1 Peptide Selection Process 
Peptides for the array were selected to represent a spectrum of biological events but 
with an emphasis on pathways and processes associated with innate immunity. A total of 194 
proteins representing signal transduction kinases, transducers and effectors were selected. Many 
of these proteins are functionally complex and undergo phosphorylation at multiple sites to 
control discrete aspects of protein behavior. Therefore, for many of these proteins multiple 
peptides, representing distinct phosphorylation events, were selected to allow more detailed 
insight into cellular responses under different treatment conditions.  
 
3.2.2 Designing Bovine Peptides 
Phosphosite (www.phosphosite.org) and Phosphobase (phospho.elm.eu.org) are publically 
available online databases that hold information on manually-curated and literature-based 
serine, threonine and tyrosine phosphorylation sites. This information is primarily focused on 
phosphorylation events characterized for either human and mouse with limited representation of 
other species such as rat. Search results for a specific protein return short peptide sequences 
corresponding to characterized phosphorylation sites. Where available, information on the 
corresponding kinase, as well as links describing the biological function of the specific 
modification, is also included. These two databases were searched for proteins of interest and 
corresponding human peptides were saved.  
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Table 3.1. List of selected chemicals, reagents and their suppliers. 
Chemicals Supplier 
Acrylamide Sigma 
Aim V media Gibco, Invitrogen Corp. 
Aprotenin Sigma 
Adenosine triphosphate(ATP) Calbiochem 
Bovine serum Albumin(BSA) Biorad Laboratories 
Bromophenol Blue Sigma 
CD14 microbeads Miltenyi Biotec Inc. 
CpG 2007 Merial 
Dithiothreitol (DTT) Biorad Laboratories 
Ethylene glycol tetraacetic acid(EGTA) Sigma 
Ethylenediamine tetraacetic acid (EDTA) Fluka BioChemika 
Fetal Bovine Serum (FBS) Gibco 
Glycerol Amersham Bioscience 
Horse radish peroxidase(HRP) Sigma 
Leupeptin Sigma 
Lipopolysaccharide(LPS) Sigma 
3-Aminophthalhydrazide(Luminol) PerkinElmer BioSignal, Inc. 
Magnesium Chloride Sigma 
Percoll Amersham Biosciences 
Phenylmethylsulphonyl fluoride(PMSF) Sigma 
Polyoxyethylene Lauryl Ether(Brij-35) ICN Biomedicals Inc. 
Sodium dodecyl sulfate(SDS) Calbiochem 
Sodium floride Sigma 
sodium orthovanadate Sigma 
Sodium pyrophosphate Sigma 
Triton 100 Sigma 
Fura-2, AM AnaSpec Inc. 
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Antibodies Supplier 
Fluorescent antibody LI-COR Biosciences 
Phospho-Etk(Y40) Cell Signaling Technology 
anti-bovine CD14  VMRD 
FITC-conjugated anti-mouse BD Bioscience 
Radioactive Chemicals Supplier 
gamma-32P Adenosine Triphosphate(ATP) 
salt 
Amersham Bioscience 
Supplier Address 
Fluka BioChemika 
Sigma-Aldrich Canada Ltd., Oakville, 
ON, Canada 
Gibco Invitrogen Ltd., Gaithersburg, MD, USA 
Calbiochem 
EMD Chemicals Inc., Gibbstown, NJ, 
USA 
ICN Biomedicals 
ICN Biomedical Canada Ltd., Saint 
Laurent, PQ, Canada 
Sigma 
Sigma-Aldrich Canada Ltd., Oakville, 
ON, Canada 
Miltenyi Biotec Inc. Miltenyi Biotec Inc., Auburn, CA, USA 
LI-COR Biosciences 
LI-COR Biosciences, Lincoln, Nebraska, 
USA 
Cell Signaling Technology 
New England Biolabs Ltd., Pickering, 
Ontario, Canada 
Amersham Bioscience 
GE Healthcare Bio-Sciences Corp., 
Piscataway, NJ, USA 
AnaSpec Inc. AnaSpec Inc., San Jose, CA, USA 
Merial 
Merial Canada Inc., Montreal, Quebec, 
Canada 
Biorad Laboratories Biorad Laboratories, Hercules, CA, USA 
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PerkinElmer BioSignal, Inc. 
PerkinElmer BioSignal, Inc., Montreal, 
Quebec, Canada 
BD Bioscience  
VMRD VMRC, Inc., Pullman, WA, USA 
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To obtain bovine-specific consensus sequences, we identified a series of human 
phosphorylation events of interest and then employed the Blastp (version 2.2.13) program 
(ncbi.nlm.nih.gov/BLAST) from NCBI to compare the collected human peptides against the 
NCBI-NR database. Blastp was set to search bovine protein records and retrieve short exact 
matches for the list of human peptides. A comparison of the protein descriptions for the query 
and hit sequences was performed to ensure that they referred to orthologous protein. 
 
3.2.3 Synthesis and Spotting of Peptides 
All peptides were synthesized and printed according to the following protocol by JPT 
Peptide Technologies (www.jpt.com). Amino-oxy-acetylated peptides were synthesized on 
cellulose membranes in a parallel manner using SPOT synthesis technology (Frank, 1992; 
Wenschuh et al., 2000). Following side chain deprotection the solid phase bound peptides were 
transferred into 96 well microtiter filtration plates (Millipore, Bedford, USA) and treated with 
200 µL of aqueous triethylamine (0.5 % by vol) to cleave the peptides from the cellulose. 
Peptide-containing triethylamine solution was filtered off and solvent was removed by 
evaporation under reduced pressure. Resulting peptide derivatives (50 nmol) were re-dissolved 
in 25 µL of printing solution (70% DMSO, 25% 0.2 M sodium acetate pH 4.5, 5 % glycerol; by 
vol.) and transferred into 384-well microtiterplates. Two droplets of 0.5 nL peptide solution 
were deposited per spot on aldehyde functionalized glass slides using the non-contact printer 
Nanoplotter of GESIM (Großerkmannsdorf, Germany) equipped with 8 piezoelectric NanoTips 
(GESIM, Großerkmannsdorf, Germany). Printed peptide microarrays were kept at room 
temperature for 5 hours, washed with deionised water, quenched for 1 hour with 50% aqueous 
hydroxylamine, washed extensively with water followed by ethanol, and dried under a stream 
of nitrogen. Resulting peptide microarrays were stored at 4 °C and maintained reactivity for 
more than 18 months. To determine intra-experimental variability in substrate phosphorylation, 
each block of 300 peptides was printed in triplicate on each slide. The final physical dimensions 
of the array were 19.5 X 19.5 mm with each peptide spot having a diameter of ~350 µm and 
peptide spots being 750 µm apart.  
A total of 298 bovine/human peptides and 2 negative peptide controls, of 15 amino 
acids in length, were printed on each block of the array according to the map presented in 
Appendix A- Figure A1. The identities of the proteins and the sites of phosphorylation are 
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presented in Appendix A- Figure A2. The sequences of all peptides are presented in Appendix 
A- Table A1. Seven positive control (Histon 1-4, Myelin basic protein- MBP bovine, and 
alpha/beta Casein) proteins were printed around each block on the array by JPT Peptide 
Technologies. Each positive control is a full length protein and is known to be phosphorylated 
in cells in presence of ATP. Signals from these controls are not included in our peptide array 
analysis as these proteins are mainly printed for visualization and gridding of the blocks. 
 
3.3 MACS Isolation of Bovine Blood Monocytes  
Blood was collected by venupuncture from mature cattle using 0.3 % EDTA as an 
anticoagulant. Blood was transferred to 50 mL polypropylene tubes and centrifuged at 1400 x g 
for 20 minutes at 20 °C. Mononuclear leukocytes were isolated from the buffy coat and mixed 
with calcium and magnesium free phosphate-buffered saline (PBSA) (1 x solution; PH 7.3) to a 
final volume of 35 mL. The cell suspension was then layered onto 15 mL of 54 % isotonic 
Percoll (GE Healthcare) and centrifuged at 2000 x g for 20 minutes at 20 °C. Peripheral blood 
mononuclear cells (PBMCs) from the Percoll-PBSA interface were collected and washed twice 
with cold PBSA (1 x solution; PH 7.3) supplemented with 0.1% EDTA and once with MACS 
buffer. Monocytes were purified from isolated PBMCs by MACS® purification using CD14 
microbeads (Miltenyi Biotec). Monocytes were plated in Aim V medium (GibcoTM, Invitrogen) 
supplemented with 10 % heat-inactivated fetal bovine serum (FBS; GibcoTM). The purity of 
monocytes was assessed by flow cytometry (BD FACSCalibur) following cell labeling with an 
anti-bovine CD14 antibody (VMRD). Cells were cultured for 19 hours prior to stimulation. 
 
3.4 Flow Cytometry Analysis 
A volume of 50 µL (2 x 107/mL) of isolated CD14+ monocytes was placed with 50 µL 
of mouse anti-bovine CD14 monoclonal antibody (mAb) (VMRD, clone number:MM61A). 
Monocytes were incubated on ice for 15 minutes and pelleted by centrifugation at 349 x g for 2 
minutes at 4°C. Next, three washes were performed with an initial 100 µL and subsequent 200 
µL of flow cytometry solution [PBSA (1 x solution; PH 7.3), 0.03 % sodium azide and 0.2% 
gelatin]. Finally a goat anti-mouse Ig polyclonal antibody (BD Bioscience) was added to the 
well and three washes similar to the first set of washes were performed. Monocytes were then 
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fixed with 200µL of 2% formaldehyde and their purity was assessed with a flow cytometry 
instrument (BD FACSCalibur) using Cellquest software. 
 
3.5 Treatment of Monocytes 
Isolated monocytes were resuspended (10x106 per mL) in Aim V medium (GibcoTM, 
Invitrogen Corp., San Diego, CA) enriched with 10 % fetal bovine serum (FBS) and were 
incubated at 37 °C overnight before any treatment. 
 
3.5.1 CpG-treatment 
CpG ODNs are often species-specific in their ability to induce innate immune responses 
and ODN 2007 (TCGTCGTTGTCGTTTTGTCGTT) has been shown to be effective for cattle 
(Nichani et al., 2006). Rested monocytes (10 x 106/mL) were stimulated with 5 µg/mL CpG 
2007 (Merial) or cultured in media for 4 hours at 37 °C. After removing the media from the 
tubes, cells were stored at -80 °C before use with the peptide arrays. A total of 2.5 x 107 
monocytes were required per peptide array. 
 
3.5.2 LPS-treatment 
Rested bovine monocytes (1.0 x 107/mL) were stimulated with 100 ng/mL E. coli LPS 
(Sigma-Aldrich). This quantity of LPS has been shown to induce cellular responses in 
monocytes isolated from humans (Mookherjee et al., 2006).Cells were pelleted and stored at  
-80 °C before use with the peptide arrays. A total of 2.5 x 107 monocytes were required per 
peptide array. 
 
3.6 Peptide Array Analysis 
 
3.6.1 Kinome Analysis of Bovine Monocytes 
Cell lysates were prepared and incubated with the arrays as reported previously (Diks et 
al., 2004) with the exception that lysate from 25 x 106 monocytes was incubated with each chip. 
Cell pellets were lysed with 100 µl lysis buffer (20 mM Tris-HCL pH 7.5, 150 mM NaCl, 1 
mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM Na3VO4, 1 mM 
NaF, 1 µg/mL leupeptin, 1 g/mL aprotinin, 1 mM PMSF), incubated on ice for 10 minutes and 
 40 
then spun in a microcentrifuge for 10 minutes at 4 ºC. A 70 µl aliquot of this supernatant was 
mixed with 10 µl of the activation mix (50% Glycerol, 50 uM ATP, 60 mM MgCl2, 0.05% v/v 
Brij-35, 0.25 mg/mL BSA, 2 mCi/mL γ-32P-ATP) and incubated on the chip for 2 hours at 37 
ºC. Finally, slides were washed once with Tris-buffered saline (PBS) (1 x solution; PH 7.3) 
containing 1 % Triton X-100, twice with 2 M NaCl containing 1% Triton X-100 and in 
demineralized H2O. 
Following air drying the arrays were exposed to a phosphoimager screen for one week. 
Images were obtained by scanning the screen with a Typhoon scanner (GE Healthcare) and 
then loaded on Arrayvision software (Image Research). Intensity values for the spots and 
background were obtained and normalization and statistical analyses were performed with 
Genespring software (Agilent Technologies).  
 
3.6.2 Measuring Signal Intensity for Array Peptides 
Radioactive signals were captured from the array by exposure to a phosphoimager 
screen over a period of one week. A phosphoimager was utilized due to ease of handling and 
availability of a scanner that would allow detection of weak signals. A Typhoon scanner (GE 
Healthcare) was set to obtain array images from the phosphoimager screen using the highest 
sensitivity settings with a pixel size of 25 microns. The captured image of the phosphoimager 
plate was then processed using ImageQuant TL v2005 software (Amersham, GE Healthcare) to 
obtain individual peptide array images. ArrayVision software (GH healthcare) was used with a 
protocol describing the spacing between spots and blocks of the array to obtain spot and 
background intensity of the spots. 
 
3.6.3 Signal Intensity Calculation 
 Arrayvision software was utilized to process peptide arrays and collect signal intensity 
data for peptide spots. First, a protocol file was created to contain the coordinates of each spot 
and the measurements of spacing between spots/blocks as well as the dimension of 
spots/blocks. More specifically, a horizontal and vertical spacing of 0.125 mm between spots, a 
distancing of 0.125 mm between two blocks, and dimension of 0.4 mm for each spot was 
specified. Three replicate blocks on the array were numbered as 1, 2, and 3 with 1 being the 
block adjacent to the slide label. In order for the program to correlate the correct spot identifier 
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to its intensity proper orientation of the slide on the image screen was necessary. When loading 
a peptide array it was rotated so that the label side was positioned to the left and the corner with 
a row as well as a column of positive controls was oriented to the bottom right.   
 When drawing grids on a slide, each spot was represented as a circle and a total of 362 
circles were present in each block. In addition to 298 bovine and 2 negative control peptides, 
there were 7 positive controls printed on four sides of each block (Appendix A- Figure A1). 
Blank spots were used to complete a row or column containing positive controls in order to 
create a proper square shape for a block. Background intensity for a spot was calculated as the 
average of pixels from 4 regions in the immediate vicinity of each spot.  
 Prior to analyzing the array data with Genespring software, data points for positive 
controls and blank spots were removed from the data file. Positive control spots and blanks 
were merely used for gridding purposes. In addition, very high intensity values for positive 
control spots would skew lower signal data from bovine peptides and preclude proper 
normalization and statistical analysis. 
 
3.6.4 Statistical Analysis on Signal Intensities 
For peptide array data, global normalization to the 50th percentile was performed on the 
raw data by Genespring software. One sample t-test was performed on the normalized data 
from the 18 replicates to evaluate reproducibility of the signal by comparing peptide signals to a 
baseline value of 1. There were two biological samples for each treatment and 9 technical 
replicates. Together, there were a total of 18 replicates for each spot under each treatment. 
A student t-test was performed on PKA and the superoxide assay results. By comparing 
results for replicates of media control to CpG or LPS samples, confidence in the differential 
production of superoxide or PKA activity was measured as a result of LPS or CpG stimulation.  
 
3.7 Western Blot Analysis 
 
3.7.1 Detection of Phosphorylated Etk 
Human blood was collected using 0.3% EDTA as an anticoagulant. PBMCs were 
isolated and CD14+ monocytes were MACS purified following the same protocols used to 
isolate bovine monocytes. Monocytes were cultured overnight, resuspended at 2 x 106/mL and 
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stimulated with 100 ng/mL LPS (Sigma-Alrich), 5 µg/mL CpG 2007 (Merial) or cultured in 
media for 4 hours at 37 °C. Stimulated cells were then pelleted and lysed with 100 µl SDS 
sample buffer [62.5 mM Tris-HCl (pH 6.8 at 25 ºC), 2% w/v SDS, 10% glycerol, 50 mM DTT, 
0.01% w/v bromophenol blue, 1 mM PMSF], denatured (5 mins at 95 ºC) and 30 µl of it was 
loaded on a 10% SDS gel and transferred to a nitrocellulose membrane. Phospho-Etk antibody 
(catalogue number 3211) (Cell Signaling Technology) and a fluorescent-conjugated secondary 
antibody (LI-COR biosciences) were used in accordance to the Supplier’s protocol. An image 
of the blot was captured using an Odyssey scanner (LI-COR Biosciences). 
 
3.8 Measuring Protein Kinase A (PKA) Activity 
Omnia TM Lysate Assay kit (Catalog number KNZ0021; Biosource) was utilized to 
measure PKA activity. Ten million bovine CD14+ monocytes were stimulated with either LPS, 
CpG or media control for 4 hours and were lysed with 50 µl Omnia Cell Extraction Buffer. The 
protein concentration was determined using Quick StartTM Protein Assay (Bio-Rad) and 50 µg 
of protein was used to carry out kinase reactions following the manufacturer’s protocol.  
 
3.9 Quantification of Oxidative Burst 
Superoxide production was measured by chemiluminescence. The protocol that was 
followed was as described (Thrasher et al., 1992) with the exception that 4 x 106 bovine 
monocytes were used without phorbol myristate acetate activation and before reading the 
luminescence, the 96 well plate was wrapped in foil and incubated at 37°C, 5% CO2 for 20 
minutes. Luminescence was measured at 30 second intervals using a Victor3V 1420 Multilabel 
Counter (PerkinElmer). 
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4.0 RESULTS 
 
4.1 Development of Bovine Peptide Array  
 
4.1.1 Available Phosphorylation Motifs for Human Proteins 
Phosphorylation of serine, threonine and tyrosine phosphorylation occurs at an 
approximate ratio of 1,000:100:1(Hunter, 1998). In addition to the large number of proteins that 
undergo phosphorylation, many of these proteins are modified at multiple sites, giving rise to 
an estimated 100,000 unique phosphorylation events within the human proteome (Zhang et 
al.,2002). Currently there are two main publically available phosphorylation based databases: 
Phosphosite and Phosphobase. There are 32,250 human phosphorylation sites on Phosphosite as 
of March, 2008. The majority of the approximately 29,000 phosphorylation sites are curated 
based on published work. The rest of the phosphorylation sites are based on unpublished 
MS/MS data. In comparison, Phosphobase holds approximately 16,000 phosphorylation sites as 
of July, 2007. Phosphobase records are based on experimentally verified phosphorylation sites 
as well.   
 
4.1.2 Comparison of Human phosphorylation motifs to Bovine Proteins  
To determine the degree of sequence conservation surrounding sites of phosphorylation 
in humans and bovine, a series of 880 peptides representing sites of phosphorylation within 
human proteins were searched against the NCBI bovine protein database by Blastp program to 
generate orthologous bovine peptides. Blastp results revealed that half of the hit sequences had 
100% identity to their query sequences (Table 4.1). Moreover, a comparison of the protein 
descriptions for the query and hit sequences confirmed that they referred to the same protein.  
From these 880 phosphorylation sites, we selected peptides for the array based on their 
biological significance and the degree of conservation of the sequence surrounding the 
phosphoacceptor site based on the premise that higher degrees of sequence conservation may 
also imply functional conservation. Of the bovine peptides included on the array 65 % 
displayed 100 % sequence conservation and the remainder showed various degrees of sequence 
similarity to their human homologous peptides. About 5 % of the array peptides were 
comprised of human peptides with no bovine hits detectable by the Blastp program (Table 4.1). 
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Table 4.1. Analysis of Bovine Kinase Target Peptides Selected from Queries of Human 
Peptides.  
 
Sequence 
Differences1 
All Bovine 
Peptides2 
Peptides on 
Array3 
Comparison of Bovine 
and Human Peptide4 
0 50% 65% Same descriptions 
1 13% 15% Same descriptions 
2 7% 8% Same descriptions 
3 4% 5% Same descriptions 
4 1.5% 1% Same descriptions 
5 0.4% 1% Same descriptions 
6 0.6% 0% Same descriptions 
0 -15 22% 5% Different descriptions or 
no hits 
 
 
 
 
1) A brief report of Blastp (version 2.2.13) results for human peptides against the NCBI-NR 
protein records for bovine organism with increasing number of peptide differences used to 
differentiate among human peptides compiled from Phosphosite and Phosphobase.  
2) An initial list of 880 human peptides was searched against the NCBI-NR protein database to 
find bovine orthologous peptides. The list is categorized based on conservation of sequence 
similarity between the query peptide and the bovine hit. 
3) Final list of 298 bovine peptides on the array is divided into 8 sections based of the number 
of amino acids that were different between a human query and bovine hit peptide.  
4) For each group of peptides, this column indicates whether query human peptides and their 
bovine homologs referred to the same proteins based on the description of their proteins. 
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4.2 Phosphorylation Activity Detection in LPS and CpG Treated Monocytes 
 
4.2.1 FACS analysis of isolated monocytes  
 Monocytes were isolated by MACS purification technique using CD14 microbeads that 
would bind to monocytes expressing CD14+ receptors. As CD14+ monocytes were isolated 
from PBMC populations, it was necessary to ensure that purified monocytes did not include 
other cell types from the PBMC population.  Purity of isolated monocytes was tested by FACS 
analysis (Figure 4.1). For this set of isolated monocytes, 98.2 % of the cells expressed CD14+ 
marker which indicates that these cells are pure monocytes. 
 
4.2.2 Bovine Peptide Array Results 
Cellular extracts of isolated bovine monocytes treated for four hours with media, 100 
ng/mL LPS or 5 µg/mL CpG ODN 2007 were subjected to kinome analysis by the arrays. 
Pseudo-images representing the averaged normalized signal for each peptide on the array were 
generated for each treatment condition (Figure 4.2). 
Individual peptide signals displayed high technical and biological (n = 2) reproducibility 
when one-sample t-test on replicate data for CpG and LPS samples produced high confidence 
levels (p<0.05) for 219 and 220 of the peptides, respectively (Appendix A- Table A3). Of 
these peptides, 92 and 98 were differentially phosphorylated following LPS and CpG treatment 
as compared to media treated cells (Figure 4.3).  
Over half of the peptides, many relating to known TLR-associated signaling molecules, 
were conserved in both identity and phosphorylation change as predicted from previous studies 
in human cell lines. These data support the conclusion that TLR4 and TLR9 signaling is highly 
conserved in bovine monocytes with many similarities in kinase activation following LPS and 
CpG stimulation (Figure 4.4). This is not unanticipated as previous reports (Miggin and 
O’Neill, 2006) have implicated similar adaptor molecules are involved in signaling by TLR 
family members and these data confirm the capacity of the current peptide arrays to 
reproducible reflect kinome changes. The remaining, differentially phosphorylated, peptides 
were either specific to a particular treatment or had different trends of phosphorylation for 
either LPS or CpG. These peptides presumably represent differential responses achieved by 
activation of the two different TLRs (Figure 4.4) (Table 4.2).  
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Figure 4.1. FACS analysis of purified CD14+ bovine blood monocytes. Isolated monocytes 
were stained with CD14 FITC and analyzed by flow cytometry. For this sample purity of 
monocytes was at 98.2%. 
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                                               A. Media 
  B. LPS 
  C. CpG 
 
Figure 4.2. Phosphorylation of substrate targets on peptide arrays by cellular lysates from 
bovine monocytes stimulated with medium (A), LPS (B), or CpG ODN (C). Purified CD14+ 
bovine monocytes (25 x 106) were cultured overnight, stimulated with 100 ng/mL LPS, 5 
µg/mL CpG ODN 2007, or cultured in media for 4 hours at 37 °C. Monocyte lysates were 
prepared and incubated with peptide arrays in the presence of γ-32P-ATP. After original slide 
images were acquired by a scanner, normalized and corrected for background noise then signal 
strength for each spot was calculated. The average signal for each peptide was calculated from 
the 18 replicates and this value was used to generate pseudo-images of peptide arrays for each 
condition assayed. For peptide identity and protein information, please refer to supplemental 
figure A1 and table A1. 
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Figure 4.3. Altered phosphorylation events following LPS and CpG ODN stimulation. The 
Venn diagram summarizes the number and pattern of significant and differentially 
phosphorylated peptides observed with LPS- and CpG ODN-stimulated cell lysates when 
compared to responses from media treated cells.  Altered phosphorylation events by LPS and 
CpG ODN were identified with fold changes less than or equal to 0.7 and greater than or equal 
to 1.4 when normalized signals were compared to signals from media control. 
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Figure 4.4. A signaling pathway based on known phosphorylation events of TLR4 and 
TLR9 in a variety of human cell lines and reflecting phosphorylation signals in bovine 
blood monocytes stimulated with LPS or CpG. A coloring scheme is used to illustrate 
phosphorylation events which were detected with the peptide array when analyzing lysates 
from bovine monocytes stimulated with LPS (TLR4) or CpG ODN (TLR9). A (+p) on a path 
indicates addition of a phosphate group to a phospho-site of the substrate protein the arrow 
points to. Solid pointed lines indicate known phosphorylation activities while dashed pointed 
lines refer to previously suggested phosphorylation interaction. Non-pointed lines show non-
phosphorylation based protein interactions. Both TLR4 and TLR9 signal through common 
adaptor proteins although the degree of phosphorylation at specific sites on the signaling 
transducers may differ. Details of the phosphorylation of peptides for individual signal 
transducers in these pathways are available in Table 2. 
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Table 4.2. Phosphorylation of substrate peptides by kinases in LPS and CpG ODN 
stimulated monocytes. 
Fold Change3  p-value4 Phospho
-protein1  
Kinase  
Target2 LPS CpG LPS CpG 
Kinase Mediating 
Phosphorylation5 
Effect of 
Phosphorylation6 
IRAK-1 T209 3.2 3.7 0.01 0.01 IRAK-1 
Required for self 
phosphorylation and 
activation  
IRAK-1 S376 1.1 7.3 0.01 0.22 IRAK-4 Activation 
IRAK-1 S568 0.2 0.2 0.01 0.01   
IRAK-1 T387 1.0 1.1 0.01 0.01   
IRAK-1 T100 1.3 1.2 0.01 0.01 Akt1 regulates transcription 
FAK Y397 2.9 2.5 0.14 0.01 FAK 
Regulates apoptosis, 
and protein degradation  
Etk Y40 7.2 1.6 0.01 0.01 FAK 
Enzymatic activation, 
altered intracellular 
location, regulates 
molecular association 
and cell motility 
PKCA S657 1.1 1.0 0.01 0.01  
Altered intracellular 
location 
p40phox T154 1.7 0.4 0.01 0.01 PKCA  
p47phox S370 4.6 3.1 0.01 0.01 PKCA, PKACa 
Enzymatic activation, 
and altered intracellular 
location 
PKACa S338 3.9 2.5 0.02 0.02   
PKACa T195/7 7.7 1.9 0.02 0.01   
Src S74 1.0 1.0 0.01 0.01   
IKKα T23 1.0 1.0 0.01 0.01 Akt2 
Regulate apoptosis, and 
enzymatic activation 
IKKβ Y188 0.4 1.1 0.56 0.01 Src 
Regulates transcription, 
and activation 
IKKγ S31 0.1 0.0 0.01 0.01 IKKβ 
Regulates proper NFkB 
activity 
IKKγ S43 2.6 0.5 0.01 0.01 IKKβ  
IkBα S32/6 0.8 0.5 0.06 0.62 
CK2-A1(S32/6), 
IKK-alpha(S32/6), 
Nik(S32/6) 
activation(S32), protein 
degradation and 
more(S32/6) 
 
IkB-β T19 0.8 0.8 0.01 0.01  Protein degradation 
IkB-ε S18 0.5 0.6 0.01 0.01  Protein degradation 
NFkB-
p100 S870/72 3.5 13.2 0.06 0.71 
Nik(S870), IKK-α 
(S872) 
Protein 
processing(S870), 
regulates association 
with cellular 
proteins(S870) 
NFkB-
p105 S337 18.4 20.5 0.02 0.01 PKACa 
Activation, and 
regulates transcription 
NFkB- S276 11.4 11.0 0.01 0.01 MSK1, PKACa Activation, regulates 
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1) Common name for substrate protein with a peptide for a phosphorylation site on the 
array. 
2) Position and name of target amino acid on the substrate protein. 
3) Fold changes for LPS and CpG samples were calculated by comparing the background 
corrected and normalized signal values of these samples to the media control. 
p65 transcription, and more 
NFkB-
p65 S311 4.3 2.3 0.01 0.01 PKCZ Activation? 
TAK1 S192 15.0 22.9 0.15 0.09 TAK1 Activation 
P38-γ T185 0.4 1.1 0.16 0.32   
p38-α 
T179/Y
181 1.3 1.4 0.88 0.76 
MKK3/6(T179/Y1
81) 
Activation, Enzymatic 
activation, and more 
(T179/Y181) 
ASK1 S966 0.2 0.4 0.01 0.01 PKD Inhibition 
MEK1 S217 1.3 1.4 0.01 0.01 Raf1 and Cot Activation 
MEK2 Y216 0.4 0.7 0.11 0.29  Inhibition 
MEK5 S311 0.9 1.1 0.01 0.01   
MEKK1 T1383 0.8 0.7 0.01 0.01 MEKK1 Activation 
MKK4 S257/0 4.1 2.9 0.01 0.01 
ASK1(S261), 
MLK3(S261) 
enzymatic 
activation(S261) 
JNK2 T404/7 0.7 1.2 0.01 0.01 
CK2-A1(T404/7), 
MKK7(T404/7) Activation(T404/7) 
Jun S63 1.9 1.6 0.01 0.01 JNK1,JNK2 
Protein activation, 
stabilization and more 
Jun S73 0.9 1.1 0.04 0.01 JNK1 
Protein activation, 
stabilization and more 
ERK1 T202/4 1.0 1.1 0.01 0.01 
Cot(T202/4), 
MEK1/2(T202/4), 
Lck(T204), 
ERK1(T204) 
Activation (T202/4), 
enzymatic activation 
(T202/4) 
 
Elk-1 S389 1.2 1.2 0.01 0.01 ERK1 
Activation, and 
regulates transcription 
Raf1 S259 1.0 1.0 0.01 0.01 PKACa Inhibition 
Raf1 S499 1.0 2.3 0.01 0.01 PKACa Activation 
Fos T232 0.2 0.2 0.05 0.01 ERK5, ERK2 
Altered intracellular 
location, and activation 
ERK2 Y204 1.2 1.0 0.01 0.01 MEK1  
TBK1 S172 1.0 1.1 0.01 0.01  Enzymatic activation 
IRF-3 S385/6 0.6 3.0 0.01 0.13 
TBK1(S385/6), 
IKK-ε(S385) 
Activation(S385), and 
regulates association 
with cellular proteins 
and more (S385/6) 
IRF-3 S396/8 7.7 27.1 0.04 0.27  
activation, regulates 
transcription, and 
more(S369), altered 
intracellular location, 
regulates association 
with cellular 
proteins(S368) 
FADD S194 10.6 5.9 0.08 0.01   
Casp8 S347 3.4 2.8 0.01 0.01   
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4) P-values reported by Genespring software for normalized phosphorylation signals. A p-
value represents confidence level on reproducibility of a signal and is evaluated by one-
sample t-test which compares normalized signals (n = 18) for each peptide to a baseline 
value 1.  
5) For phosphorylation sites with known upstream kinases, Phosphosite database provides 
names of these kinases. Available information from Phosphosite is listed here.  
6) Curated data on Phosphosite database maintain information on effects of 
phosphorylation on cellular activity of a substrate protein. When available, such 
information was presented here. 
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4.2.2.1 Activation of the Known Toll-like Receptor Pathways 
Signaling events associated with TLR activation have been identified using a variety of 
techniques, including immunoprecipitation, site mutagenesis and mass spectrometry. These 
analyses have been performed with a variety of human and mouse cells and provide a 
framework to determine if TLR signaling pathways are conserved in bovine monocytes 
(Miggin et al., 2006). Patterns of phosphorylation observed for proteins of this pathway which 
are present on the array are presented in (Figure 4.4) along with phosphorylation details in 
(Table 4.2). Selected phosphorylation events, and their potential biological significance are 
further discussed. 
  
IRAK-1: This is an important upstream kinase in TLR signaling pathways (Miggin et 
al., 2006). IRAK-1 undergoes a series of phosphorylation events during activation resulting in 
its release from the receptor complex to interact with TLR adaptor molecules such as TRAF6 
(Miggin et al., 2006). It has been established that phosphorylation of T209 of IRAK-1 is a 
prerequisite for TLR-mediated activation in human embryonal kidney cells (Kollewe et al., 
2004). Consistent with this observation, a peptide corresponding to this site of bovine IRAK-1 
undergoes a 3.2 and 3.7-fold increase in phosphorylation following LPS and CpG stimulation, 
respectively (Table 4.2). The increased phosphorylation of this site under both treatment 
conditions indicates that IRAK-1 is a conserved signal transduction kinase for both TLR4 and 
TLR9 in bovine monocytes.  
Our array also contained peptides representing putative IRAK-1 phosphorylation sites 
which have yet to be defined with respect to biological roles. For example, the degree of 
phosphorylation of peptides representing T100 and T387 was independent of TLR4 or TLR9 
activation. In contrast, phosphorylation of the peptide corresponding to S568 of IRAK-1 
displayed a 5-fold decrease in phosphorylation following either LPS or CpG treatment. Finally, 
levels of phosphorylation of S376 increased 7.3-fold in response to CpG treatment but 
remained unchanged following LPS stimulation relative to the media control (Table 4.2). 
Collectively these results confirm the prerequisite modification of IRAK-1 at T209 for 
TLR-induced signal transduction but also suggest that regulation of IRAK-1 through 
phosphorylation is more complex and multi-faceted involving aspects of regulation through 
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phosphorylation which are independent of TLR activation, conserved for various TLRs and 
specific to particular TLRs. 
 
NF-κBs: The NF-κB family of transcription factors is one of the key effectors for TLR 
signaling by both TLR4 and TLR9. In addition to regulation through programmed degradation 
of inhibitory proteins, NF-κB is controlled through phosphorylation. Phosphorylation events 
relating to the regulation of key NF-κB proteins, such as p65, p100 and p105 are represented on 
our peptide array. As anticipated (Perkins, 2006) increased levels of phosphorylation of critical 
regulatory sites within NF-kB and related kinases were observed following both the LPS and 
CpG treatment conditions.  
 
NF-kB p105/p50: The ability for the NF-κB p105 sub-unit to bind DNA and function 
as a transcription factor depends upon phosphorylation of S337, as reported through studies in a 
variety of mammalian cell systems (Hou et al., 2003). A peptide representing this 
phosphorylation event undergoes one of the most dramatic changes in phosphorylation as a 
result of both LPS and CpG treatment with 20 and 18-fold increases in phosphorylation, 
respectively (Table 4.2).  
 
NF-kB p100/p52: Activation of p100 is dependent upon phosphorylation of a series of 
C-terminal sites including S870 (Xiao et al., 2004). While both LPS and CpG stimulation 
resulted in increased phosphorylation of this site the effect was more pronounced with CpG 
(13.2-fold) versus LPS (3.5 fold) stimulation (Table 4.2). 
 
NF-kB p65: Similarly, investigations of the transactivation domain of the p65 NF-κB 
subunit indicate that S276 is the major phosphorylation site for this protein and modification of 
this residue is essential for p65-dependent cellular responses in murine embryonic fibroblasts 
(Okazaki et al., 2003). Consistent with the established role of the p65 subunit in mediating 
cellular responses for various Toll-like receptors we observed a 11-fold increase in 
phosphorylation of this residue upon stimulation with LPS and CpG (Table 4.2). 
Phosphorylation of S311 has also been implicated in activation of p65 NF-κB in murine 
 55 
embryonic fibroblasts (Duran et al., 2003) and the bovine peptide corresponding to displayed 
significantly increased phosphorylation following LPS and CpG stimulation (Table 4.2). 
 
TAK1/MAP3K7: TAK1 is a member of the mitogen-activated kinase kinase kinase 
(MAP3K) family which serves as an important link between the Toll-like and MAPK 
pathways. TAK1 is activated by an early intermediate of the TLR pathway, TRAF6, which 
forms active signaling complexes with TAK1 following its activation by IRAK-1. The bovine 
peptide array included a peptide representing S192, a known phosphorylation site for TAK1 
activation in human embryonic kidney cells (Kishimoto et al., 2000). This kinase target 
underwent 22.9 and 15.0-fold increases in phosphorylation with LPS and CpG treatments, 
respectively. Conversely, a second peptide corresponding to T184 of TAK1, which has not 
been implicated in TLR-mediated signaling, did not undergo differential phosphorylation as a 
consequence of either LPS or CpG treatment (Table 4.2). TLR activation of the MAPK 
signaling pathway was supported by increased phosphorylation of peptides corresponding to 
activating events of v-raf-1 murine leukemia viral oncogene homolog 1(Raf1), jun oncogene 
(Jun), and mitogen-activated protein kinase kinase 4(MKK4) (Table 4.2). While Raf1 is an 
upstream protein kinase of the MAPK pathway, MKK4 lays mid point and Jun is a downstream 
transcription factor.  
 
IRF3: In response to microbial nucleic acids, IRF3 is activated through phosphorylation 
of S396 in human embryonic kidney cells (Servant et al., 2003). Phosphorylation of this site 
has also been reported with LPS (McCoy et al., 2008). IRF3 therefore presents an interesting 
opportunity to test the hypothesis that differential phosphorylation plays a role in determining 
cellular responses to TLR signaling. Following LPS stimulation there was a 7-fold increase in 
S396 phosphorylation but no significant change in phosphorylation was observed following 
CpG treatment (Table 4.2). This observation provides independent confirmation that the 
peptide arrays can reveal discreet events involved in the regulation of complex biological 
responses. Furthermore, this observation provides substantial evidence for the conservation of 
TLR signaling events across disparate species and cell types. 
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FADD/Casp8: In addition to its apoptotic function FADD also plays a role in TLR-
induced proliferative responses (Imtiyaz et al., 2006). FADD is activated through a direct 
interaction with the IRAK-1 MyD88 signaling complex following TLR stimulation (Zhande et 
al., 2007) which then induces cellular responses through activation of Casp8 (Beisner et al., 
2005). FADD-mediated activation of Casp8 has been observed following LPS, and to lesser 
extent, CpG treatment (Alappat et al., 2005). We also observed increased phosphorylation of 
peptides corresponding to activating events for FADD and Casp8; S194 of FADD by 10.6 and 
5.9-fold and S347 of Casp8 by 3.4 and 2.8-fold following LPS and CpG treatments, 
respectively (Table 4.2). The activation of these proteins, and the higher degree of activation 
observed with LPS treatment, provides further evidence that TLR signaling is highly conserved 
across species and within a variety of cell types.   
 
FAK and Etk: Based on reported crosstalk with MyD88, activation of FAK through the 
TLR system has been suggested (Zeisel et al., 2005). Interestingly, a peptide corresponding to 
Y397 of FAK, a phosphorylation event associated with activation of this kinase in human 
embryonic kidney cells (Glover et al., 2004) was increased by 2.9 and 2.5-folds following LPS 
and CpG stimulation of bovine monocytes.  
 FAK is known to activate members of the Bruton’s tyrosine kinase (Btk) family which 
has defined roles in integrin signaling, promoting cell migration (Chen et al., 2001), and has 
been implicated in TLR signaling (Doyle et al., 2007). Etk is a Btk family member, although a 
specific role for Etk in TLR signaling has not been reported. Activation of Btk by FAK (Chen 
et al., 2001) does, however, provide a possible link with TLR signaling. The bovine peptide 
arrays included a peptide corresponding to Y40, the key regulatory phosphorylation site in Etk. 
Phosphorylation of this peptide was increased over 7-fold following LPS stimulation and 1.6-
fold following CpG (Table 4.2). 
Consistent with the bovine kinome results from our peptide array, stimulation of the 
human monocytes with LPS, but not CpG resulted in phosphorylation of Y40 of Etk (Figure 
4.5). To our knowledge this is the first report of evidence linking Etk activation with LPS 
stimulation. This association was first revealed by data obtained from the peptide array and 
highlights the utility of this approach for analyzing cell signaling events. 
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4.2.2.2 Activation of Receptor-specific Pathways 
 In addition to the general TLR4 signaling pathway activated through MyD88 and 
TRAF6 adaptor molecules, TLR4 specific pathways include adaptor molecules TRIF/TRAM 
and subsequent activation of effector proteins such as IRF3 and NF-kB (Yamamoto et al., 
2002b; Hoebe et al., 2003; Oshiumi et al.,2003a). A peptide representing phosphorylation site 
S396, that is implicated in activation of IRF3, is present on the peptide array. Following LPS 
stimulation there was a 7-fold increase in S396 phosphorylation but no significant change in 
phosphorylation was observed following CpG treatment (Table 4.2). Clearly, TLR4 signaling 
through TRIF/TRAM has allowed phosphorylation activity of this site following LPS 
stimulation.  
Activation of IRF3 is reported to induce TNFα production which is then secreted from 
the stimulated cells and binds to its receptor (TNFR) (Covert et al., 2005). Signaling induced by 
TNFR also culminates in NF-κB activation. In this way endotoxin can cause a prolonged 
transcriptional activation that is important for the defense of the host. TRIF in contrast to the 
other adapter proteins is shown to be important for the induction of apoptosis in response TLR4 
(Han et al., 2004; Ruckdeschel et al., 2004; De Trez et al., 2005; Kaiser and Offermann, 2005). 
Along with TRIF this pathway requires involvement of the proteins RIP1, FADD, and caspase-
8. We observed increased phosphorylation of peptides corresponding to activating events for 
FADD and Casp8; S194 of FADD by 10.6 and 5.9-fold and S347 of Casp8 by 3.4 and 2.8-fold 
following LPS and CpG treatments, respectively (Table 4.2). Although, these results indicate 
activation of FADD and Casp8, it is evident that LPS stimulation results in a higher level of 
phosphorylation for these peptides. It is possible that these proteins are activated through a 
conserved pathway for TLR4 and TLR9 as well as an LPS specific pathway through 
TRIF/TRAM adaptor molecules. 
Mal is another cytoplasmic receptor that binds the TIR domain of TLR4. Previous 
reports indicate phosphorylation of this adaptor by a Btk kinase which is required for 
degradation of Mal (Mansell et al., 2006), providing a means of termination of its signaling. Etk 
is a member of the Btk family of kinases. The bovine peptide arrays included a peptide 
corresponding to Y40, the key regulatory phosphorylation site in Etk. Phosphorylation of this 
peptide was increased over 7-fold following LPS stimulation and 1.6-fold following CpG 
(Table 4.2).  
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Figure 4.5. Etk protein phosphorylated due to LPS stimulation of CD14+ human 
monocytes. Phosphorylation of Etk in human monocytes cultured with media, or stimulated 
with LPS (100 ng/mL), or CpG ODN 2007 (5 µg/mL) for 4 hours was detected by a phospho-
Etk antibody reacted with a Western blot.  
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Consistent with the bovine kinome results from our peptide array, stimulation of the human 
monocytes with LPS, but not CpG resulted in phosphorylation of Y40 of Etk (Figure 4.5). 
 
4.3 Physiological Responses of LPS and CpG Treated Monocytes 
 
4.3.1 Western Blot with Phospho-Ekt Antibody 
The unknown role of Etk in TLR-mediated responses, the differential phosphorylation 
of the Y40 peptide under the LPS and CpG stimulation conditions and the availability of a 
commercial phosphospecific antibody for Y40 of Etk made it a strong candidate for more 
detailed investigation. 
A human Etk-specific monoclonal antibody is available for the Y40 site. In spite of the 
high degree of conservation of the human and bovine Etks, in particular around the 
phosphoacceptor site, this antibody did not cross react with the bovine protein (data not shown), 
highlighting one of the technical limitations of antibody-based kinome analysis. Based on the 
anticipated shared biological role of Etk in humans and bovine cells, we examined the 
phosphorylation status of Etk from human CD14+ monocytes in response to LPS and CpG 
treatments. Human monocytes are previously reported to express TLR4 and TLR9 and respond 
to LPS and CpG ligands respectively (Bosisio et al., 2002; Hornung et al., 2002; Doyle et al., 
2007). 
Consistent with the bovine kinome results from our peptide array, stimulation of the 
human monocytes with LPS, but not CpG, resulted in phosphorylation of Y40 of Etk (Figure 
4.5). To our knowledge this is the first report of evidence linking Etk activation with LPS 
stimulation. This association was first revealed by data obtained from the peptide array and 
highlights the utility of this approach for analyzing cell signaling events. 
 
4.3.2 Measuring Protein Kinase A (PKA) Activity 
A previous kinomic investigation with peptide arrays indicated increased 
phosphorylation of numerous targets of PKA in response to LPS stimulation of human 
peripheral blood mononuclear cells (Diks et al., 2004). PKA is a central cellular kinase which is 
regulated through both cAMP availability as well as phosphorylation of the catalytic sub-unit of 
PKA (PKACa) at T197. The bovine peptide arrays revealed increased phosphorylation at the 
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orthologous region of PKACa. LPS stimulation increased T197 peptide phosphorylation nearly 
8-fold higher than the media control and 4-fold more than CpG ODN stimulation (Table 4.2). 
Another PKACa target S338 was phosphorylated due to LPS and CpG stimulation at 3.9 and 
2.5 fold increase, respectively (Table 4.2). 
To determine if increased phosphorylation of PKACa corresponded directly to increased 
PKA activity we used a substrate assay to monitor PKA activity in cell lysates. Purified bovine 
monocytes were stimulated with LPS, CpG ODN, or control medium using the same culture 
conditions and time used for the peptide arrays. Within 4 hours, LPS stimulation induced a 
significantly (p = 0.02) greater increase in PKA activity than media stimulated cells and CpG 
ODN stimulation did not significantly (p = 0.2) increase PKA activity relative to the media 
control (Figure 4.6). Although phosphorylation of two sites, T195/7 and S338, were observed 
with peptide arrays following CpG and LPS stimulation, the PKA assay suggests that 
phosphorylation of T195/7 is more reflective of PKACa activation. Furthermore, it can be 
argued that a 1.9 phosphorylation fold change increase of T195/7 by CpG during the kinome 
analysis is not a significant increase to reflect cell signaling responses. Therefore, it is critical 
that kinome studies be complemented by functional assays to determine the biological 
significance of kinome changes. 
 
4.3.3 Oxidative Burst 
As a mechanism of innate immune defense the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase catalyzes the reduction of oxygen to superoxide (O2-) at the 
expense of NADPH (Johnson et al., 1998). NADPH oxidase is not constitutively active but 
exposure of cells to appropriate stimuli results in rapid activation of enzymatic activity. 
Activation of the oxidative burst is closely associated with signaling by the Toll-like system 
with p47 (PHOX) serving as a direct target for IRAK-4 in human neutrophils (Pacquelet et al., 
2007). Differential levels of oxidative burst in response to TLR ligands have been reported for 
chicken and turkey monocytes and heterophils. Not all TLRs utilize the same signaling pathway 
to activate this response (Farnell et al., 2003; He et al., 2006). 
P47(PHOX) activation involves phosphorylation at numerous sites but modification of 
S370 has been identified as one of the earliest and most significant activation events in human 
leukocytes (Johnson et al., 1998).  
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Figure 4.6. PKA activity in bovine monocytes following LPS and CpG ODN stimulation. 
Purified CD14+ monocytes were stimulated with 100 ng/mL LPS, 5 µg/mL CpG, or culture 
medium for 4 hours before being lysed. Reagents were added to the lysate and incubated for 20 
minutes at 37°C, 5% CO2 before reading chemiluminescence every 30 seconds during a 30 
minute interval. Monocytes were isolated from three animals and triplicate cultures were 
analyzed for each condition. The slope of the PKA activity was calculated for each replicate 
and these values were averaged for each biological replicate. Student t-tests carried out on 
slopes of PKA (n = 9) showed significant increase for LPS (p = 0.02) but not CpG (p = 0.2) 
stimulated cells when compared to medium cultured cells. Fold changes for LPS and CpG were 
calculated in relation to results from medium cultured cells.  
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The bovine peptide array revealed increased phosphorylation of P47PHOX at the S370 position 
following both LPS (4.6 fold) and CpG ODN (3.1-fold) stimulation of monocytes. These data 
suggest activation of oxidative burst following both stimuli, but that this activation was more 
efficient following TLR4 stimulation. 
The activity of NADPH oxidase is also influenced by p40(PHOX) which interacts with 
p47(PHOX) in a phosphorylation-dependent manner to regulate oxidative burst. 
Phosphorylation of p40(PHOX) at position Thr154 has been reported to inhibit NADPH 
oxidase in a semirecombinant cell-free system (Lopes et al., 2004). Oxidative burst is therefore 
dependent upon both activation of p47(PHOX) through phosphorylation at S370 as well as 
removal of p40(PHOX) mediated inhibition through dephosphorylation of this regulatory 
protein at T154. Phosphorylation of the bovine peptide orthologous to T154 of p40(PHOX) was 
decreased 2.5-fold with lysate from CpG stimulated monocytes but increased 1.7-fold following 
LPS stimulation. This differential phosphorylation of T154 in p40 (PHOX) led us to 
hypothesize that CpG ODN, but not LPS stimulation, results in increased oxidative burst 
activity in bovine monocytes. 
Purified CD14+ monocytes were stimulated using the same stimulation conditions as 
employed for the peptide arrays. CpG ODN stimulation as compared to media cultured cells 
induced a significant level (p = 0.04) of oxidative burst while LPS stimulation caused lower 
oxidative burst than media control cells but not by a significant amount (p = 0.5) (Figure 4.7). 
The oxidative burst assay was consistent with phosphorylation changes for the regulatory 
p40(PHOX) and support the conclusion that p47phox phosphorylation does not directly 
correlate with cellular responses. This kinome analysis provides direct evidence for one 
mechanism by which TLR signaling may result in differential activation of the oxidative burst 
in monocytes. 
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Figure 4.7. Superoxide production in LPS and CpG ODN stimulated monocytes. Bovine 
monocytes were stimulated with 100 ng/mL LPS, 5 µg/mL CpG or cultured in medium for 4 
hours before the addition of luminol and HRP. The monocytes were then incubated for 20 
minutes at 37°C, 5% CO2 to allow the reaction to begin. Following incubation a luminescence 
reading was taken every 30 seconds for 30 minutes. Fold change calculation was based on data 
from the mean and one standard deviation of values from 3 biological samples which were 
analyzed in duplicate.  Fold changes for LPS and CpG were calculated in relation to results 
from media cultured cells. Student t-tests (n = 6) confirmed a significant increase in superoxide 
by CpG (p = 0.04) but not LPS stimulation (p = 0.5) when compared to cells compared to 
medium. 
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5.0 DISCUSSION 
 
5.1 Kinome and Phosphoproteome 
In spite of the undetermined function of many protein kinases, the medical significance 
of this class of enzymes is readily apparent. For example, in cancer, approximately half of the 
genes directly linked to the disease encode protein kinases, the remainder encode products that 
either regulate kinases or are acted upon by them (Blume-Jensen and Hunter, 2001). Similar 
underlying defects in phosphorylation physiology have been linked to diabetes (Chrissobolis 
and Sobey, 2006), Alzheimers (Avila, 2006), inflammation (Vermeulen et al., 2006) as well as 
numerous other disorders. The medical significance of the protein kinases has prompted 
extensive research efforts with an estimated quarter of drug discovery efforts of pharmaceutical 
and biotechnology groups being focused on protein kinase inhibitors (McInnes, 2006): As a 
result, 60 such kinase inhibitors are currently in advanced clinical trials. With the appreciation 
that many cellular responses occur independent of changes in transcription or translation there 
is an increasing interest in defining cellular responses at the level of post-translation 
modification of proteins. Analysis of cellular phosphorylation events can be conceptually 
divided into two categories, kinome and phosphoproteome analysis. Kinome analysis focuses 
on the protein kinases while phosphoproteome analysis focuses only on the protein targets of 
kinases.  
 
5.2 Design of a Bovine Peptide Array 
 
5.2.1 Non-Specific Peptides 
This category defines peptides on the bovine array that are either human peptide 
sequences without bovine orthologous peptides or peptide sequences that are conserved across 
members of a protein family. Therefore, prior to assigning biological functions to these peptide 
targets on the basis of bovine experimental results, validation of phosphorylation activity is 
required. 
Although, each peptide on the array uniquely identifies a single bovine protein, a set of 
peptides were created to represent conserved phosphorylation motifs across members of the 
same protein family. For example, peptide sequence TSFMMTPYVVTRYYR with a target 
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tyrosine is 100 % conserved between JNK1 and JNK3 with one amino acid difference in JNK2. 
Similarly three peptides representing conserved phosphorylation motifs for members of 
MKK(3,6), Smad(1, 2, 3), and Akt(1, 3) as well as peptides conserved across isomers of 
PKC(A, B, C) and IKK (A, B) are printed on the array (Table 5.1). 
A peptide target (QNRSGAMSPMSWNSD) for human FADD (S194) was included in 
the pool of peptides on the array (Table 5.1). Blastp query did not return a bovine orthologous 
peptide for this sequence; however, due to the significance of FADD in some of the signaling 
pathways, it was decided to print the human peptide sequence on the array. A protein record for 
bovine FADD protein (accession number Q645M6) was available. Closer investigation of 
Q645M6 revealed conservation of S194 on the bovine FADD. We acquired a peptide sequence 
of 15 amino acids with S194 in position 9 (QSGSANPGSFTAWDS) which was printed on the 
array. Although, S194 is conserved between human and bovine FADD proteins, the degree of 
similarity surrounding S194 is very low.  
There are 13 additional human peptide sequences (Table 5.1) on the array. Similar to 
human FADD (S194), for a number of phosphorylation targets involving proteins such as IκB-
β, TNF-R1 and Nik no equivalent bovine peptides were identified, although bovine orthologous 
proteins are available. Either these bovine sequences are not correctly annotated or the 
phosphorylation targets in the orthologous proteins have not been sufficiently conserved to 
match the human sequence when using the current search criteria utilized. 
 
5.2.2 Non-Reacting Peptides  
TRAF6 is an important adaptor protein in early stages of TLR signaling pathways. 
Searches of Phosphosite and Phosphobase databases did not produce any previously reported 
phosphorylation motifs for TRAF6. However, some research groups have generated potential 
phosphorylation motifs based on computer analysis of TRAF6 sequence. After consulting a 
generated list of phosphorylation motifs by JPT Peptide Technologies, seven potential target 
peptides for S12, S48, S97, T83, T317, T486 and T429 were selected. Data analysis of bovine 
experiments revealed that S12, S97 and T486 did not produce significant phosphorylation 
signals due to exposure to cell lysates from CpG, LPS stimulated, or media cultured bovine 
monocytes.  It is possible that these predicted targets are not involved in phosphorylation 
supported by the fact that no previous phosphorylation reports are available. Alternatively, it is 
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possible that these sites are not phosphorylated in the context of the cell type and stimulants 
used during this investigation. Although S48, T83, and T429 were phosphorylated by active 
kinases in medium cultured lysates, in contrast to LPS and CpG stimulated monocytes. 
Consistent lack of phosphorylation signals for 21 additional peptides was an indication 
these peptides may not be phosphorylation sites (Table 5. 2). These peptides either require 
additional substrate structural components/domains to interact with the appropriate kinases or 
they are not phosphorylated in the context of the cell type and stimulants used during this 
investigation. 
 
5.3 Biological Relevance of Kinome Responses of LPS and CpG Treated Monocytes 
 
5.3.1 Activated Signaling Pathways 
With our bovine peptide arrays we demonstrated the ability to characterize complex 
signaling events through two different TLRs. We confirmed activation of known and shared 
signaling pathways as well as discovering novel signaling events both shared by, or specific to, 
each Toll-like receptor, including oxidative burst, protein kinase A (PKA) activity and 
activation of kinases not previously associated with Toll-like signaling. 
The bovine peptide arrays confirmed the utility of this approach for characterizing 
complex signaling events. We used the arrays to analyze cell signaling events within bovine 
monocytes following stimulation by two agonists known to target distinct TLRs. TLR4 and 
TLR9 are known to share conserved signaling pathways but there are also reports that each 
TLR may also utilize unique signaling proteins (Miggin and O'Neill, 2006) This would be 
consistent with emerging evidence that leukocytes display distinct cellular responses to each 
TLR agonist (Muzio et al., 2000). Our kinome analysis confirmed that TLR4 and TLR9 
signaling in bovine monocytes displayed a remarkable level of conservation when comparing 
between TLRs (Figure 4.3).  
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Table 5.1. A list of non-specific peptides. 
Phospho-protein Kinase 
Target 
Human peptide Sequence Bovine peptide Sequence 
JNK1/2/3 Y185 TSFMMTPYVVTRYYR TSFMMTPYVVTRYYR 
PKCA/B/C T323 GVTTKTFCGTPDY DGVTTKTFCGTPDYI 
MKK3/6 S98 GYLVDSVAKTMDAGC GYLVDSVAKTMDAGC 
IKKα/β T180 DQGSLCTSFVGTL LDQGSLCTSFVGTLQ 
Smad1/2/3 S405 GSPSVRCSSMS LTQMGSPSVRCSSMS 
Akt1/3 T310 DGATMKTFCGTPEY KDGATMKTFCGTPEY 
Akt1/3 S173 RPHFPQFSYSASS RPHFPQFSYSASATA 
FADD S194 QNRSGAMSPMSWNSD 
 
 
NF-κB (p105) S907 QAHSLPLSPASTRQQ  
P53 S6/9 MEEPQSDPSVEPPLSQ  
PKCE T710 TREEPVLTLVDEAIV  
IRAK-1 S568 WQPLAAPSGASAQAA  
P300 S893 SELLRSGSSPNLNMG  
P300 S1834 MLRRRMASMQRTGVV  
TRAIP S497 IKTEVPGSPAGTEGN  
TRAIP S690 IDGATQSSPAEPKSE  
IkB-β S131/15 SGPCSSSSDSDGGDE  
IkB-β T19/23 DEWCDTGLGSLGPDA  
TNF-R1 S274 LAPNPSFSPTPGFTP  
Akt3 T447 TAQTITITPPEKYDE  
Nik T559 TGDYIPGTETHMAPE  
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Table 5.2. A list of non-reacting peptides 
Phospho
-protein 
Kinase 
Target 
LPS-
fold 
CpG-
fold Human peptide Bovine peptide 
ATF-4 S245 1.0 0.8 TRGSPNRSLPSPGVL SRGSPNKSLLSPGAL 
NFAT2 S245 0.9 1.1 PSTSPRASVTEESWL PSTSPRTSVTEESWL 
BATF T48 1.0 2.0 QKSRQRQTQKADTLH QKSRQRQTQKADTLH 
Jak1 Y1022/3 0.3 0.6 AIETDKEYYTVKDDR AIETDKEYYTVKDDR 
ITK Y512 0.8 0.4 RFVLDDQYTSSTGTK RFVLDDQYTSSTGTK 
Btk Y222 1.0 1.8 
LKKVVALYDYMPMN
A 
LKKVVALYDYMPMN
A 
DOCK2 Y221/4 1.0 1.0 MSKDQPDYAMYSRIS MSKDQPDYGMYSRIS 
RelB S573 1.0 1.5 AFGGGLLSPGPEAT AGFGGGLLSPGPEAT 
BLNK Y72 1.0 1.0 SDDFDSDYENPDEHS SDDFDSDYENPDEHS 
VEGFR-
2 Y1214 1.0 1.0 VCDPKFHYDNTAGIS VCDPKFHYDNTAGIS 
RAC1 S71 1.0 1.0 YDRLRPLSYPQTDVF YDRLRPLSYPQTDVF 
FGFR1 Y463 1.0 1.0 MLAGVSEYELPEDPR MLAGVSEYELPEDPR 
FGFR3 Y760 1.4 0.9 TVTSTDEYLDLSAPF TVTSTDEYLDLSVPF 
Src S74 1.0 1.0 NSSDTVTSPQRAGPL NSSDTVTSPQRAGPL 
PKG1 T58 1.0 1.0 THIGPRTTRAQGISA THIGPRTTRAQGISA 
Fes Y713 1.0 1.5 REEADGVYAASGGSR REEADGIYAASGGLR 
RasGAP Y460 0.4 0.8 TVDGKEIYNTIRRKT AVDGKEIYNTIRRKT 
Fas Y291 1.0 1.0 LHGKKEAYDTLIKDL SHGKKNAYCTLTKSL 
ASK1 S83 1.0 1.0 ATRGRGSSVGGGSRR ATRCRGNSGGGGGRR 
TRAF6 S12 1.1 1.2 ENSCGSSQSESDC  HCENSCGSSQSESDC 
TRAF6 S97 0.9 0.9 KACIIKSIRDAGH  CKACIIKSIRDAGHK 
TRAF6 S48 0.8 0.4 LSSSFMEEIQ  TVTLSSSFMEEIQGY 
TRAF6 T486 0.9 0.8 EALRQRTFIKDDT  LEALRQRTFIKDDTL 
TRAF6 T317 0.4 0.3 HQIRELTAKMETQ  DHQIRELTAKMETQS 
TRAF6 T83 0.1 0.1 LREAVQTPCGHRF  ALREAVQTPCGHRFC 
TRAF6 T429 0.6 0.1 PWPFQGTIRLTIL  LPWPFQGTIRLTILD 
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Furthermore, a comparison with previous analyses in other species and cell types also revealed 
a remarkable conservation of kinome activity for TLR4 and -9 in bovine monocytes (Figure 
4.4). This observation supports the conclusion that there was a relatively high level of accuracy 
when annotating orthologous genes in the bovine genome.   
Kinome analysis also revealed a substantial component of cell signaling that was unique 
to each TLR (Figure 4.3). Some of the phosphoproteins implicated in the TLR cell signaling 
pathways had been identified in previous studies using a variety of other techniques and cell 
lines (Figure 4.4). There were also a number of kinase targets which had not been previously 
implicated in TLR signaling. We have shown that by using a peptide array many cellular 
phosphorylation activities that were previously investigated by laborious methodologies in 
various cell types can be quickly studied in a single cell population and species of interest.  
The development and use of peptide arrays for kinome analysis are in early stages of 
development. Therefore, careful interpretation of data and application of functional assays to 
validate phosphorylation results is necessary. The rationale behind these arrays is to provide a 
relative measure of activity for individual kinases under different treatment conditions.  
Most appropriately these arrays can be used to provide a broad overview of kinome activity 
which can then be validated through independent, species-specific techniques.  
As demonstrated here, validation of peptide array observations can be done with 
functional assays or phosphorylation-specific antibodies. A PKA assay, for example, allowed 
us to identify the specific site of PKACa corresponding to activation of this enzyme. Moreover, 
a superoxide assay facilitated proper interpretation of a complex interaction between 
p47(PHOX) and its inhibitor p40(PHOX) which was not apparent from our peptide array 
results. Finally, a phospho-Etk antibody was utilized to validate a phosphorylation activity of 
this substrate in human monocytes due to the lack of a bovine specific phospho-antibody.   
 
5.3.2 Biological Rationale for Distinct TLR Responses 
TLR9 and TLR4 belong to two different subsets of the TLR family: TLR4 is a cell 
membrane receptor and TLR9 is located intracellularly in endosomal compartments. Being 
located on the plasma member, TLR4 can detect its ligand rapidly. On the other hand detection 
of CpG by TLR9 depends on intracellular localization of DNA first. Such cellular activity can 
cause a delay in cell responding to DNA as compared to LPS. Previous reports indicate that 
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TNF production by human monocytes occurs at 4 hours as compared to 18 hours by CpG 
(Hartmann and Krieg, 1999). We would expect earlier activation of the general TLR signaling 
pathway and NF-kB as well as earlier production of TNF by LPS as compared to CpG. At 4 
hour time point during our experiments, it is evident that activation of this TLR pathway is 
variable by LPS and CpG stimulation (Figure 4.3).  
TLR4 location on the cell surface allows its exposure to external stimuli. Thus, TLR4 
has evolved to trigger the innate immune responses in a more efficient manner through two sets 
of adaptor molecules. Our results show that pathways specific to TLR4 are also activated 
during the LPS stimulation of bovine monocytes. More specifically, we were able to show that 
IRF3 which is phosphorylated through TRIF/TRAM adaptor complex is activated and 
subsequently induced activation events of FADD and Casp8 proteins (Table 4.2).  
Kinome responses and functional assays on bovine monocytes were performed at a 4-
hour time point. From kinome responses of bovine monocytes to CpG ODN and LPS, we 
observed conserved and differential phosphorylation activities in these monocytes due to LPS 
and CpG ODN. Previous research indicates that long term stimulation of cells with LPS inhibits 
activity of IRAK-4 which in turn affects downstream signaling pathways by TLR4 (Hatao et 
al., 2004). In addition, comparison of LPS and CpG stimulated human monocytes have shown 
high sensitivity and earlier responses of monocytes to LPS at 4 hour time and a longer 18 hours 
time point to CpG (Hartmann and Krieg, 1999). As this investigation was carried out at a single 
time point, the differences that were observed between TLR4 and TLR9 signaling could have 
been transient and not reflective of biological differences. A series of experiments at early and 
late time points can shed more light into the complex TLR signaling networks.  
 
5.4 Advantages and Disadvantages of Peptide Arrays 
It is now possible to use information from phosphoproteome investigations to create 
tools to investigate both the kinases; the kinome, and their targets the phosphoproteome. One 
advantage of kinome analysis is that focusing on enzymatic activity, rather than product 
abundance, enhances the sensitivity of detecting changes in kinase activity. This approach also 
enables development of high throughput tools which can simultaneously assess changes in a 
large number of preselected phosphorylation events. 
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The present investigation clearly demonstrated an additional advantage of using peptide 
arrays for kinome analysis. The conservation of many phosphorylation sites within orthologous 
proteins enables the rapid creation of peptide arrays for kinome analysis in species for which 
limited phosphorylation databases exist but genomic information is available. This 
bioinformatics approach eliminates the need to generate and characterize species-specific and 
phosphorylation-specific antibodies. The present data (Table 4.1 and Table 4.2) confirm that it 
is possible to identify conserved and divergent phosphorylation sites in orthologous proteins 
using protein databases from other species. This enables the rapid design of kinase substrate 
peptides to incorporate species-specific variances. While many of the resulting sites are 
absolutely conserved with respect to the protein sequences surrounding the phosphoacceptor 
sites, there is sufficient species-specific variation to justify the utility of a bioinformatics 
approach (Table 4.1). Such customization of arrays can be taken a step further by development 
of arrays focused on specific biological responses or cell functions. The bovine array used in 
the current investigation was biased for phosphoprotein targets known to be involved in innate 
immune signaling pathways.  
The use of peptide arrays for kinome analysis is still in the early stages of development 
and there are a number of technical and biological challenges which need to be addressed. For 
example, while the arrays are designed to monitor kinase activity as a marker of signal 
transduction activity biologically, the net degree of phosphorylation of a particular target 
reflects the dual and opposing contributions of both kinase and phosphatase activity. The 
presence of a panel of phosphatase inhibitors within the cellular extracts analyzed here negates 
the contribution of these enzymes to the net phosphorylation status of a particular target in 
order to simplify analysis of kinase activity.  
In some cases peptide substrates may not serve as ideal ligands for the corresponding 
protein kinase. This could manifest itself in a number of ways. Firstly, a peptide may be 
recognized and phosphorylated by kinases other than those which mediate physiological 
phosphorylation. This would result in false positives or overestimation of the extent of 
phosphorylation which would occur with the cellular protein. It is also possible that peptides on 
the array make available substrate targets that are not present within the particular cell type. 
Alternatively, that individual peptides may be recognized with differing degrees of efficiency 
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by their respective kinases makes it difficult to use the absolute measure of phosphorylation of 
a given peptide as an indicator of the level of activity of the corresponding kinase. 
A species-extrapolated peptide array will experience the same limitations as a peptide 
array created for species with well-defined phosphorylation information with one additional 
challenge. A paralog protein rather than an ortholog may produce matches of up to 100 % 
sequence similarity for the phosphorylation motif of interest. Inclusion of such peptides on the 
array will produce false positive signals.  
  
5.5 Future Direction 
Peptide array technology has evolved in the past few years and like any new technology, 
it has not reached its full potential. Currently commercial arrays are available for human 
research. As progress in peptide array technology continues, arrays of increasing complexity 
will become available to researchers. These advancements will undoubtedly include an 
expansion of the breadth of arrays available for different organisms, as well as kinome subsets, 
such as for specific organelles. One method to develop focused and species-specific array is 
reported here. 
 Based on the principle that a high degree of amino acid conservation for 
phosphorylation targets exists among mammalian species, a peptide array for bovine species 
was developed encompassing phosphorylation targets for innate immune signaling transducers 
and effector molecules. Development of this tool was achievable mainly because bovine 
genome was sequenced in 2005 and much effort has been directed towards prediction of 
proteins and functional annotations of bovine genes. As a result, many sequences for bovine 
proteins of interest are available in public databases. However, for many predicted kinase 
substrates, phosphorylation sites are not calculated and their biological significance is 
unknown. We successfully inferred phosphorylation information for approximately 140 
proteins and 298 phosphorylation targets of bovine species by utilizing publically available 
databases and bioinformatics tools. Furthermore, we were able to validate biological function of 
many of the inferred phosphorylation sites quickly by applying the peptide array to a well 
studied signaling pathway. Currently, efforts are directed towards genome sequencing of many 
organisms and the methodology developed here can be utilized to annotate phosphorylation 
sites for other species as soon as their genomes become available. In addition, similar focused 
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arrays can be developed for subsets of the kinome such as all kinases involved in a particular 
disease or cell function.  
The quality of our array can be improved in the future by removing non-specific 
peptides from the pool and adding controls for each peptide. In addition, current array holds 
some peptides which carry more than one phosphorylation targets. Phosphorylation signal for 
such a peptide may result from activity of more than one kinase. While measuring 
phosphorylation signals for such a peptide, we can not predict whether all the targets or one site 
is phosphorylated. In such cases, we can have representative peptides where one 
phosphorylation site is present and the rest are replaced with amino acids that do not participate 
in phosphorylation. A variation of this method can be utilized to investigate significance of 
having a combination of the phosphorylation sites present simultaneously. In addition, for 
peptides holding a single phosphorylation target, controls can be created by replacing the target 
amino acid with a non-phosphorylation amino acid.   
A tremendous amount of phosphorylation data was generated during this investigation. 
There are approximately 100 peptides that are differentially phosphorylated by CpG or LPS 
when compared to media control. By applying functional assays we have validated few of these 
responses and interpreted interactions between signaling molecules in superoxide production, 
PKA activity and Etk phosphorylation. However, much work is needed to validate the 
remaining peptide array results and interpret phosphorylation based signaling pathways such as 
Smad and Stat pathways whose members are present on the array. In addition, we have 
identified new phosphorylation targets for some of the proteins that were not reported 
previously. New targets of TLR9 and TLR4 signaling pathways can be identified by 
understanding the significance of these previously unknown phosphorylation targets.  
As our bovine peptide array holds transcription factors, such as NF-kB, a parallel 
investigation of transcription activity in stimulated monocytes will enhance the validity of our 
kinome analysis. As phosphorylation may correspond to activation of a transcription factor, by 
performing real-time PCR to test expression of target genes, we can validate our kinome 
results. Alternatively, a large scale gene expression analysis can be carried out by utilizing 
oligo or cDNA microarrays.  
As kinome analysis of cells was carried out at a single time point, the differences that 
were observed between TLR4 and TLR9 signaling could have been transient and not reflective 
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of biological differences. To further investigate, a series of experiments at early and late time 
points need to be carried out. These peptide arrays are excellent tools to evaluate transient and 
time dependency nature of these kinome responses.  
Controversy exists regarding expression of TLR9 on human, bovine and mouse 
monocytes. Recent investigations have reported that human monocytes express TLR9 and 
respond to CpG through NF-kB pathway (Hornung et al., 2002; Doyle et al., 2007). Here we 
have demonstrated that bovine monocytes respond to CpG through activation of NF-kB as well. 
We assume that such signaling activity is initiated by TLR9 receptor on bovine monocytes. 
However, it is possible that CpG ODN triggers these cellular responses through other TLR 
signaling pathways. In this investigation we have assumed that CpG ODN modulates responses 
through the TLR9 receptor. Therefore, it is necessary to study expression of TLR9 on these 
cells through gene expression or marker expression techniques. An alternative would be to 
study kinome responses of TLR9-/- bovine monocytes and compare kinome responses to 
present investigation.    
Peptide arrays for kinome analysis allow for characterization of global patterns of signal 
transduction activity as well as dissection of dynamic patterns of phosphorylation which can 
occur at distinct sites of the same protein to regulate unique biological objectives allowing for 
much more descriptive analysis of how particular pathways, and individual proteins, and being 
post-translationally adapted to different stimuli. We anticipate these arrays will be of 
considerable utility to rapidly screen specific cell populations to determine if they can respond 
to an agonist and whether this response is conserved when compared to the same cell type from 
other species or different cell types within the same species.  
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7.0 Appendices 
 
Appendix A  
 
 
 
 
 
 
Figure A1. Mapping of the Bovine Peptide Array. An illustration of the positioning of the 
300 peptides (including the negative controls) and the positive controls (black spots) on a 
block; an array holds three replicate blocks of the same configuration. Positive controls (Histon 
1-4, MBP bovine, and alpha/beta casein) proteins are printed around the borders of each block 
for visualization purposes.  
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CD45(S999\02\03) 
Bad(S118) 
Etk(Y40) 
CTLA-4(Y201) 
PXN(Y31) 
CSK(Y184) 
Crk(Y221) 
NGFR(Y336) 
FRS3(Y416) 
TrkC(Y516) 
TrkB(Y706\7) 
VEGFR3(Y1265) 
VEGFR3(Y130\1) 
VEGFR-2(Y1214) 
VEGFR-1(Y1169) 
7 
PLCG1(Y783) 
PLCG1(Y771) 
PLCG1(Y472) 
PKR(T451) 
FLT3(Y597\9) 
FLT3(Y589\91) 
gp130(Y814) 
gp130(S782) 
gp130(Y767) 
MEK2(Y216) 
PIK3R1(S607\8) 
Kit(S821) 
Kit(Y721) 
RIPK1(Y384\7\9) 
ROCK2(S1133\4) 
IKK-α(T23) 
mucin 1(T1227\9) 
PDGFRb(Y740) 
PDGFRb(Y579\8
1) 
CSFR(Y809) 
CSFR(Y561) 
PPP2CA(T304) 
PTP1B(S50) 
Nik(T559) 
8 
eNOS(S1176) 
Grb10(S150) 
IFNGR1(Y479) 
IFNGR1(Y457) 
Jun(S73) 
Jun(S63) 
STMN1(S62) 
STMN1(S15\Y15) 
CDK2(T160) 
CDK2(T14) 
Pyk2(Y402) 
CDK7(T170) 
cyclin D1(T286\8) 
p300(S1834) 
p300(S893) 
CD28(Y206\9) 
HSP70(Y525) 
HSP27(S82\83) 
EphA2(Y772) 
EphA2(Y594) 
EphA2(Y588) 
EphA1(Y781) 
p47phox(S370) 
p40phox(T154) 
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9 
WASP(Y291) 
Syk(Y525/6) 
Cot(S400) 
CaMK2-α(T286) 
smMLCK(S1773) 
MKP-1(S359) 
MKP-1(S323) 
MKP-1(S296) 
PLCB1(S887) 
PLCB1(T333\4\6) 
BLNK(Y96) 
BLNK(Y72) 
DAPP1(Y139) 
RelB(S573) 
APE1(S289) 
Tyk2(Y1054\5) 
p70S6Kb(S473) 
CXCR4(Y157) 
CCR5(S336\7) 
CCR2(Y139) 
IL7R(Y449) 
IL1A(S87) 
IL-16(S143\4) 
IL4R(Y713) 
10 
IL2RB(Y536) 
IL2RB(Y364) 
IL-10R-A(Y496) 
IKK-β(Y199) 
IKK-β(Y188) 
HMGA1(T52) 
LEF-1(S166) 
LEF-1(T155) 
DOCK2(Y209\212) 
CBP(S2063) 
DNA-PK(T2638) 
DNA-PK(T2609) 
PKR(T446) 
Btk(Y550) 
Btk(Y222) 
ITK(Y512) 
FAK(Y397) 
TAK1(S192) 
TAK1(T184) 
PKACa(S338) 
PKACa(T195\7) 
Akt3(T447) 
Akt3(S120) 
Akt1(Y326) 
11 
Akt1(S129) 
ERK3(S189) 
ERK2(Y205) 
ERK1(T202/4) 
TBK1(S172) 
Jak3(Y981) 
Jak2(Y1007\8) 
Jak1(Y1022\3) 
JNK1(S377) 
p38-α(Y323) 
p38-α(T179\Y181) 
axin-1(S486) 
Notch 2(S2070) 
Notch 2(T1808) 
GSK3-β(Y216) 
GSK3-β(S9) 
Elk-1(T417) 
Elk-1(S389) 
Fos(T232) 
Casp8(S347) 
Casp3(S150) 
IRAK-1(S568) 
IRAK-1(T387) 
IRAK-1(S376) 
12 
IRAK-1(T209) 
IRAK-1(T100) 
FADD(S194) 
HIF2A(T840) 
HIF1A(T796) 
XIAP(S87) 
BATF(T48) 
NFAT4(S163\5) 
NFAT2(S294) 
NFAT2(S245) 
NFAT1(S326) 
NFAT1(S168) 
Smad4(T277) 
Smad3(S422\3\5) 
Smad3(S208) 
Smad2(S255) 
Smad2(T8) 
Smad1(S462\3\5) 
ATF-4(S245) 
ATF-2(T51\3\5) 
ATF-2(S44) 
IRF-5(S437) 
IRF-
3(S402\T404) 
IRF-3(S396) 
13 
IRF-3(S385\6) 
CTNNB1(S675) 
CTNNB1(Y142) 
CTNNB1(T41) 
CTNNB1(S33) 
STAT6(Y641) 
STAT5B(Y699) 
STAT5B(S731) 
STAT4(S721) 
STAT4(Y693) 
STAT3(S727) 
STAT3(Y705) 
STAT2(Y690) 
STAT1(S727) 
STAT1(Y701) 
IKK-G(S43) 
IKK-G(S31) 
NFkB-p105(S907) 
NFkB-p105(S337) 
NFkB-p65(S536) 
NFkB-p65(S311) 
NFkB-p65(S276) 
NFkB-
p100(S870\2) 
NFkB-
p100(S866\Y868) 
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X 
1 
Empty 
Empty 
Empty 
Empty 
Empty 
Empty 
Empty 
Empty 
Empty 
Empty 
Empty 
Empty 
QNRSGAMSPMSWNSD 
DRNTFRHSVVVPYES 
MEEPQSDPSVEPPEE 
SSQTSQDSGNYSNED 
VFLRCVKYVFFPSSK 
TSFMMTPYVVTRYYR 
RPHFPQFSYSASATA 
KDGATMKTFCGTPEY 
LTQMGSPSVRCSSMS 
LDQGSLCTSFVGTLQ 
GYLVDSVAKTMDAGC 
DGVTTKTFCGTPDYI 
2 
DTAGQEDYDRLRPLS 
PILKPRYYSISSSRD 
VFTMRLKSRQNLQSP 
IEFVNQYYGSFKEAK 
PSFVGSSSGNTSTTL 
LAKDGRPSFVGSSSG 
SSMSVEAETTTTFSP 
EQLRQWSSCRHIRRS 
SAINSRETMFHKERF 
SETTVELYSLAERCR 
TRGQPVLTPPDQLVI 
QSDFEGFSYVNPQFV 
QEEFKGFSYFGEDLM 
TREEPVLTLVDEAIV 
PEEKTTNTISKFDNN 
PSEGEESTVRFARKG 
EDHSAPPSPEEKDSG 
ATRCRGNSGGGGGRR 
HTLPSPPSPLASMAP 
SHGKKNAYCTLTKSL 
TDVDLGKYIPSIAEQ 
PPPPVQETLCWCQPV 
LAPNPSFSPTPGFTP 
NSTRFPPSPLASKPA 
3 
ARKKWKQSVRLISLC 
FHDDELQTDGNRCSH 
NIANSATYGFKSGTA 
KEKLGYTGESSVQAA 
PTAGALYSGSEGDSE 
QKRREILSRRPSYRK 
TIAESEDSQESVDSV 
PVYSPPGSPPPGDPR 
EEKERTFSFCGTIEY 
PDNQPLKTPCFTLHY 
AIKVEPVSPPYYSEK 
SQRQRSTSTPNVHMV 
VKSRWSGSQQVEQPT 
FVDEYDPTIEDSYRK 
AVDGKEIYNTIRRKT 
REEADGIYAASGGLR 
THIGPRTTRAQGISA 
RKSKRRSSEFEIFVD 
ESQYDSGIESLRSLR 
DEWCDTGLGSLGPDA 
SGPCSSSSDSDGGDE 
DSMKDEEYEQMVKEL 
DDRHDSGLDSMKDEE 
LPWPFQGTIRLTILD 
4 
ALREAVQTPCGHRFC 
DHQIRELTAKMETQS 
LEALRQRTFIKDDTL 
TVTLSSSFMEEIQGY 
CKACIIKSIRDAGHK 
HCENSCGSSQSESDC 
TQLVNSIAKTYVGTN 
ISLLNVFTPQKTLEE 
MSTEQTLASDTDSSL 
ELDHERMSYLLYQML 
NEYLRSISLPVPVLV 
ARLASKGTGAGEFQG 
RQADSEMTGYVVTRW 
LGETKQETLTNISAV 
EFKNIFGTPEFVAPE 
REWHKTTQMSAAGTY 
GQLIDSMANSFVGTR 
SGDSRPCSSPCELLG 
IGDFGLATVKSRWSG 
LGYRDSGYYWEVPPS 
LIDAAGDTPGAEDDE 
QGRDKYKTLRQIRQG 
MERERRASNAGGPPA 
FDKDGNGYISAAELR 
5 
VALYDYESRTETDLS 
NSSDTVTSPQRAGPL 
DDFYTATEGQYQQQP 
PLPTGVLTPPQSSKK 
DSGFCLDSPGPLDSK 
GSSESTDSGFCLDSP 
IDGATQSSPAEPKSE 
IKTEVPGSPAGTEGN 
RVYQTSPTDEDEEDE 
RTRVRANSKSEGSPV 
EEPPDHQYYNDFPGK 
DIYETDYYRKGGKGL 
LEHRQLNYIQVDLEG 
AEEQVHTYVNTTGVQ 
TVTSTDEYLDLSVPF 
ANCTHDLYMIMRECW 
LLAVSEEYLDLRLTF 
NRMPVAPYWTSPEKM 
DIHHIDYYKKTTNGR 
MLAGVSEYELPEDPR 
STFIGEHYVHVNATY 
RDVYDKEYYSVHNKT 
LQARRGKKKSGCLVL 
SPYKFSSSPLRIPGG 
6 
STRPPTLSPIPHIPR 
PAATEDLYVEMLQAS 
FQAETTVYVIVRCKL 
YDRLRPLSYPQTDVF 
GQLVDSIAKTRDAGC 
IERLRTHSIESSGKL 
PGGTLFSTTPGGERR 
PPGDYSTTPGGTLFS 
MVPTFEQYQFLYDVI 
SEQDSDESSDDDSDL 
GRELRRMSDEFHVSF 
LTKTNLSYYEYDKMK 
SPLTTGVYVKMPPTE 
FLSEETPYSYPTGNH 
VAAQDEFYRSGWALN 
GGPEPGPYAQPSVNT 
LKGDGGLYSSLPLAK 
EPPRQLNYIQVELKG 
PVIENPQYFRQGHNC 
RDVYSTDYYRVGGHT 
FPMTPTTYKGSVDNQ 
RHSLAARYYNWVSFP 
VCDPKFHYDNTAGIS 
VQQDGKDYIPLNAIL 
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7 
EGRNPGFYVEANPMP 
IGTAEPDYGALYEGR 
KLAEGSAYEEVPTSV 
RTSKKGTLRYMSPEQ 
YIDFREYEYDLKWEF 
TGSLDNEYLYIDFRE 
GILPRQRYFKQNCSQ 
QVFSRSESTQPLLDS 
STVVHSGYRHQVPSV 
KLCDFGVSGQLIDSM 
ENTEDQYSLVEDDED 
ARDIKNDSNYVVKGN 
CNDSTNEYMDMKPGV 
EEANYHLYGSRMDRR 
HIGLDSSSIGSGPGD 
EMRERLGTGGFGNVC 
PPGSTKRSPYEEVSA 
PGESDGGYMDMSKDE 
VSSDGHEYIYVDPMQ 
DIMNDSNYIVKGNAR 
ESYEGNSYTFIDPTQ 
RGEPHVTRRTPDYFL 
RNRYRDVSPFDHSRI 
TGDYIPGTETHMAPE 
8 
TSRIRTQSFSLQERH 
PELCGPGSPPALTPG 
GKESLIGYRLTADSR 
NTTTSFGYDKPHVLV 
VGLLKLASPELERLI 
KNSDLLTSPDVGLLK 
AAEERRKSHEAEVLK 
KELEKRASGQAFELI 
GVPVRTYTHEVVTLW 
EKIGEGTYGVVYKAR 
CSIESDIYAEIPDET 
GSPSRAYTHQVVTRW 
VDLACTPTDVRDVNI 
MLRRRMASMQRTGVV 
SELLRSGSSPNLNMG 
PGPTRRHYQPYAPAR 
MVQEAEKYKAEDEVQ 
RALSRQLSSGVSEIQ 
EDDPEATYTTSGGKI 
TYVDPHTYEDPNQAV 
QLKPLKTYVDPHTYE 
LDNFDGTYETQGGKI 
PAVPPRPSADLILHR 
LRRLRPRTRRVKSES 
9 
RETSKVIYDFIEKTG 
ALRADENYYKAQTHG 
EDQPRCQSLDSALFE 
SCMHRQETVDCLKKF 
GLSGRKSSTGSPTSP 
SALSYLQSPITTSPS 
HCSAEAGSPAMAVLD 
KQRRSIISPNFSFMG 
HSQPAPGSVKAPAKT 
INSSHNTYLTAGQLA 
EEAGDDSYEPPPVEQ 
SDDFDSDYENPDEHS 
KVEEPSIYESVRVHT 
AGFGGGLLSPGPEAT 
DYFLLSHSLLPALCD 
AVPEGHEYYCVREDG 
PPSGTKKSKRGRGRP 
LLAEKVVYVGVWLPA 
EAPERVSSVYTRSTG 
ILLTIDRYLAIVHAV 
GSSQEEAYVTMSSFY 
ILKKRRLSLNQFITD 
SSIKQRISSFETFSS 
LGNGIIYSALTCHLC 
10 
LTLNTDAYLSLQELQ 
SCFTNQGYFFFHLPD 
LPALAKGYVQQDPPE 
ELLEQQKYTVTVDYW 
SFVGTLQYLAPELLE 
KEPSEVPTPKRPRGR 
TYSDEHFSPGSHPSH 
SHAVHPLTPLITYSD 
MSKDQPDYGMYSRIS 
PPRSISPGALQDLLR 
MAGQVRATQQQLDFT 
LTPMFVETQASQSTL 
LKNDETRTSKKGTLR 
RYVLDDEYTSSVGSK 
LKKVVALYDYMPMNA 
RFVLDDQYTSSTGTK 
TTPETDDYAEIIDEE 
HMTNNKGSAAWMAPE 
GTACDIQTHMTNNKG 
EEEEIRVSINEKCGK 
RVKGRTWTLCGTPEY 
TAQTITITPPEKYDE 
EEERMNCSPTSQIDN 
EVLEDNDYGRAVDWW 
11 
SGSPGENSGAEEMEV 
YSHKGHLSEGLVTKW 
IMLNSKGYTKSIDIW 
HTGFLTEYVATRWYR 
EDDEQFVSLYGTEEY 
LPLDKEYYVVREPGQ 
VLPQDKEYYKVKEPG 
AIETDKEYYTVKDDR 
GVIRGQPSPLGAAVI 
DEPVADPYDQSFESR 
RHTDDEMTGYVATRW 
MRTPGCQSPGPGHRS 
DEYNVTPSPPGTVLT 
RTPSLALTPPQAEQE 
RGEPNVSYICSRYYR 
SGRPRTTSFAESCKP 
ISVDGFSTPVVLSPG 
LSPIAPRSLAKLSFQ 
GGLPEAATPESEEAF 
FTGLKCPSLIGKPKI 
FRGDYCRSLTGKPKL 
WQPLAAPSGASAQAA 
RTRTVRGTLAYLPEE 
GSSPSQSSMVARTQT 
12 
LHEICQGTHDFSEEL 
LRARDIITAWHPPAP 
QSGSANPGSFTAWDS 
YLLPELTRYDCEVNV 
ESGLPQLTSYDCEVN 
IGRHRRVSPNCRFIN 
QKSRQRQTQKADTLH 
SYRESSLSPSPASSI 
PQGSPRVSVTDDTWL 
PSTSPRTSVTEESWL 
PPKMWKTSPDPSPVS 
YREPLCLSPASSGSS 
GSRTAPYTPNLPHHQ 
LTQMGSPSIRCSSVS 
DAGSPNLSPNPMSPT 
ELSPTTLSPVNHSLD 
MSSILPFTPPVVKRL 
LTQMGSPHNPISSVS 
SRGSPNKSLLSPGAL 
IVADQTPTPTRFLKN 
FGPARNDSVIVADQT 
FSGELSWSADSIRLQ 
NSDPLSLTPDQYMAC 
NTVDLHISNSDPLSL 
13 
IARQGGASSLENTVD 
QDYKKRLSVELTSSL 
AVVNLINYQDDAELA 
HSGATTTAPSLSGKG 
QSYLDSGIHSGATTT 
MGKDGRGYVPATIKM 
TAKAVDGYVKPQIKQ 
TYMDQAPSPAVCPQP 
PSDLLPMSPSVYAVL 
TEKGDKGYVPSVFIP 
NTIDLPMSPRTLDSL 
DPGSAAPYLKTKFIC 
NPEERKKYLKHKLIF 
TDNLLPMSPEEFDEV 
DGPKGTGYIKTELIS 
PAMLHVPSEQGTPET 
QDMLGEESSLGKPAM 
QAHSLPLSPASTRQQ 
FVQLRRKSDLETSEP 
SGDEDFSSIADVDFS 
RTYETFKSIMKKSPF 
SMQLRRPSDRELSEP 
DSAYGSQSVEQEAEK 
STEVKEDSAYGSQSV 
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Table A3. Complete set of data for the peptide arrays with CpG and LPS treated 
monocytes. 
Fold 
Change p value Protein 
Name Target LPS CpG LPS CpG 
Upstream 
kinase Phosphorylation effects 
FADD 
(human) S194 0.8 0.6 0.01 0.01   
p53 S215 0.9 0.9 0.01 0.01   
p53 S6/9 1.0 0.9 0.01 0.01 ATM(S6/9) 
Activation (S6), regulates 
apoptosis (S6/9), and more 
(S6/9) 
IFNAR1 S535 1.8 8.5 0.01 0.01  
Regulates association with 
cellular proteins , protein 
degradation 
IFNAR1 Y466 0.9 0.9 0.01 0.01 Tyk2 
Regulates association with 
cellular proteins 
JNK1 Y185 0.7 0.7 0.01 0.01   
Akt1 S173 0.7 0.9 0.15 0.12   
Akt1 T310 1.1 1.0 0.01 0.01   
smad2 S405 1.3 1.3 0.01 0.01   
IKKA T180 0.9 0.4 0.06 0.49   
MKK3 S98 0.9 0.7 0.01 0.01   
PKCA T323 1.8 1.7 0.01 0.01   
Cdc42 Y64 0.2 0.4 0.03 0.09 Src Regulates cell growth 
iNOS S909 0.8 0.7 0.01 0.01   
iNOS S739 0.4 1.0 0.50 0.01   
iNOS Y151 0.5 1.0 0.73 0.01 Src 
Altered intracellular location , 
enzymatic inhibition  
IL-8R-B 
S351/2/
3 1.2 1.6 0.01 0.01   
IL-8R-B S347 0.4 1.2 0.01 0.01  
Receptor internalization , protein 
degradation , altered receptor 
desensitization  
CCR7 
T372/3/
4 0.2 0.1 0.01 0.01   
CCR7 S356/7 0.3 0.3 0.18 0.16   
PKCT T219 0.8 0.7 0.01 0.01 PKCT Altered intracellular location 
PKCT Y90 1.1 1.1 0.01 0.01 Lck  
Regulates transcription, 
activation 
PKCA T637 1.2 0.7 0.74 0.17   
PKCA S657 1.1 1.0 0.01 0.01  Altered intracellular location 
PKCE S729 0.9 0.7 0.01 0.01 PKCE Activation 
PKCE T710 0.9 1.0 0.01 0.01   
PKCB T323 0.9 0.8 0.01 0.02   
PKCB 
S15/T1
6 0.9 1.1 0.30 0.01   
ASK1 S1033 1.1 1.1 0.29 0.18   
ASK1 S83 1.0 1.0 0.01 0.01 Akt Inhibition 
Daxx 
S668/7
1 0.9 0.7 0.57 0.18  
Altered intracellular 
location(S668), regulates 
association with cellular 
proteins(S668) 
Fas Y291 1.0 1.0 0.01 0.01  Regulates apoptosis , altered 
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intracellular location , regulates 
association with cellular proteins 
Fas Y232 0.8 0.7 0.01 0.01  
Regulates apoptosis , altered 
intracellular location , regulates 
association with cellular proteins 
TNFRSF
5 T254 0.2 0.4 0.08 0.26  
Regulates association with 
cellular proteins , activation 
TNF-R1 S274 0.6 0.7 0.48 0.46   
DAPK1 S735 0.3 0.3 0.06 0.07 ERK2  Enzymatic activation 
DAPK1 S308 1.3 1.0 0.01 0.01 DAPK1 
Regulates cell growth, regulates 
apoptosis , regulates association 
with cellular proteins, enzymatic 
inhibition 
Bid T59 1.8 3.4 0.01 0.01 CK2-A1  
Cntrll(-)  0.4 1.1 0.05 0.33   
Cntrl(-)  0.0 0.0 0.01 0.01   
SRF S77/79 0.9 1.1 0.31 0.94 
CK2-
A1(S77/79) Regulates transcription(S77) 
CREB S129 0.4 2.3 0.01 0.05 GSK3B 
Regulates transcription, 
transcription 
CREB S111/4 0.6 5.1 0.01 0.01 
ATM, CK2-
A1  
Inhibition(S111), 
phosphorylation(S114), 
regulates transcription and 
more(S111) 
MSK2 S347 0.9 0.8 0.01 0.01  Activation 
MSK2 S196 0.8 0.2 0.31 0.03 p38-α Enzymatic activation , activation 
MSK1 T581 0.9 0.9 0.01 0.01 
p38-α, ERK2, 
ERK1 Enzymatic activation 
PPARG S112 0.3 0.9 0.02 0.05 ERK2 
Regulates transcription, protein 
degradation 
Raf1 S259 1.0 1.0 0.01 0.01 PKACa Inhibition 
Raf1 S499 1.0 2.3 0.01 0.01 PKACa Activation 
H-Ras-1 T35 0.9 1.0 0.01 0.01   
RasGAP Y460 0.4 0.8 0.01 0.01   
Fes Y713 1.0 1.5 0.01 0.01 Fes 
Enzymatic activation, regulates 
association with cellular proteins 
PKG1 T58 1.0 1.0 0.01 0.01 PKCA  Enzymatic activation 
TPH1 S58 0.8 0.7 0.01 0.01   
IkB-
epsilon S18 0.5 0.6 0.01 0.01  Protein degradation 
IkB-β T19 0.8 0.8 0.01 0.01  Protein degradation 
IkB-β 
S313/1
5 0.7 0.8 0.67 0.82  Regulates transcription(S313/5) 
IkB-α Y42 1.1 0.5 0.80 0.21 
IKK-epsilon, 
IKK-β 
Activation, protein degradation, 
transcription 
IkB-α S32/36 0.8 0.5 0.06 0.62 
CK2-A1 
(S32/6),IKK-α 
(S32/6), Nik 
(S32/6) 
Activation(S32), protein 
degradation and more(S32/6) 
TRAF6 T429 0.6 0.1 0.01 0.01   
TRAF6 T83 0.1 0.1 0.01 0.01   
TRAF6 T317 0.4 0.3 0.08 0.01   
TRAF6 T489 0.9 0.8 0.01 0.01   
TRAF6 S48 0.8 0.4 0.01 0.01  
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TRAF6 S97 0.9 0.9 0.01 0.01   
TRAF6 S12 1.1 1.2 0.02 0.01   
MEK5 S311 0.9 1.1 0.01 0.01   
JNK3 T131 1.0 1.0 0.01 0.01 CDK5  
JNK2 T404/7 0.7 1.2 0.01 0.01 
CK2-A1 
(T404/7), 
MKK7 
(T404/7) Activation(T404/7) 
JNK2 S129 2.3 1.5 0.11 0.02   
ASK1 S966 0.2 0.4 0.01 0.01 PKD Inhibition 
MEKK1 T1383 0.8 0.7 0.01 0.01 MEKK1 Activation 
P38 γ T183/5 0.4 1.1 0.16 0.32   
DAPK3 T225 0.9 0.9 0.01 0.01 DAPK4 Activation 
DAPK3 T180 1.0 0.8 0.01 0.01 DAPK3 Activation 
MLK3 T278 1.2 1.1 0.01 0.01   
MEK1 S217 1.3 1.4 0.01 0.01 Raf1 and Cot                      Activation 
Mos S25 0.5 1.2 0.32 0.29   
B-Raf T598 6.0 2.3 0.54 0.05 Ras Activation 
A-Raf Y301 0.9 2.2 0.01 0.06   
JIP1 T103 1.1 1.8 0.92 0.01 JNK2, JNK1 
Regulates association with 
cellular proteins 
Ezrin T566 1.0 1.2 0.01 0.03 
GRK2, Akt2, 
ROCK1 
Cytoskeletal reorganization, 
altered intracellular location, 
regulates association with 
cellular proteins , activation 
VASP S156 1.0 0.7 0.01 0.01 PKG1, PKACa  regulates transcription  
Calmodul
in Y99 2.2 3.4 0.01 0.01   
Src S96 0.9 0.9 0.71 0.93   
Src S74 1.0 1.0 0.01 0.01   
Lyn Y507 0.6 0.6 0.03 0.02 CSK  
cyclin E1 T395 1.6 1.3 0.01 0.01 
GSK3B, 
CDK2, 
GSK3A  
Regulates cell cycle, regulates 
association with cellular 
proteins, protein degradation, 
enzymatic inhibition 
Cdc25A S88 0.9 1.1 0.01 0.01  
regulates cell cycle, protein 
degradation 
Cdc25A S82 1.4 1.3 0.01 0.01  
Regulates cell cycle, association 
with cellular proteins, protein 
degradation 
LRRFIP1 S690 1.1 2.1 0.01 0.01   
LRRFIP1 S497 1.1 1.0 0.01 0.01   
TNIK T987 1.1 1.1 0.13 0.08   
TNIK S764 0.6 0.8 0.03 0.01   
Shc1 Y349/0 0.9 0.8 0.01 0.01 Src(Y349/50) 
Regulates apoptosis(Y349/50), 
regulates association with 
cellular proteins(Y349/50) 
IGF1R Y1166 0.7 0.6 0.01 0.01  
Enzymatic activation, regulates 
association with cellular 
proteins. 
FRS2 Y435 0.6 0.5 0.33 0.21  
Regulates association with 
cellular proteins. 
FRS2 Y195 0.9 0.8 0.03 0.05   Regulates association with 
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cellular proteins (mouse) 
FGFR3 Y760 1.4 0.9 0.01 0.01  
Enzymatic activation, regulates 
association with cellular proteins 
FGFR3 Y724 1.4 1.4 0.04 0.02 FGFR3  
enzymatic activation, regulates 
association with cellular 
proteins, not reported 
FGFR4 Y754 0.9 0.7 0.01 0.01 FGFR4  
FGFR1 Y154 0.7 1.4 0.34 0.72 FGFR1 
Cytoskeletal reorganization , 
receptor internalization , protein 
degradation , altered receptor 
desensitization  
FGFR1 Y653/4 5.7 6.4 0.05 0.01 
FGFR1(Y653/
4) Activation(Y653/4) 
FGFR1 Y463 1.0 1.0 0.01 0.01  
Regulates cell cycle , regulates 
transcription 
Met Y1349 1.0 0.9 0.01 0.01 Met, Abl 
Regulates cell growth , regulates 
association with cellular proteins 
Met 
Y1234/
5 1.0 1.0 0.01 0.01 Met(Y1234/5) 
Enzymatic activation (Y1234/5), 
phosphorylation (Y1234/5), 
activation (Y1234/5) 
RhoA S188 1.1 0.9 0.02 0.26   
Rb S795 1.3 0.9 0.02 0.07  CDK6, CDK5 
Regulates cell cycle, inhibition , 
regulates association with 
cellular proteins 
Rb S780 0.8 0.7 0.01 0.01  CDK6, CDK4 
Regulates cell cycle , regulates 
apoptosis , inhibition , regulates 
association with cellular proteins 
BCAP y459 0.9 0.9 0.01 0.01   
BCAP Y195 0.9 0.8 0.81 0.57   
RAC1 S71 1.0 1.0 0.01 0.01 Akt1 Inhibition 
MKK4 
S257/6
1 4.1 2.9 0.01 0.01 
ASK1(S261), 
MLK3(S261) Enzymatic activation(S261) 
MKK4 S80 1.1 0.8 0.01 0.11 Akt Inhibition 
4E-BP1 T45 0.6 0.9 0.04 0.23 mTOR 
Inhibition, regulates association 
with cellular proteins, regulates 
translation 
4E-BP1 T36 2.5 1.6 0.01 0.01 mTOR Inhibition, regulation translation 
CD45 Y1216 1.0 1.0 0.67 0.69 CSK 
Activation, regulates association 
with cellular proteins 
CD45 
S999/0
2/03  0.9 1.0 0.05 0.01 
CK2-A1 
(S999/02/03) 
Enzymatic 
activation(S999/02/03) 
Bad S118 1.9 0.3 0.54 0.03 PPP2CB 
Regulates apoptosis, altered 
intracellular location, association 
with cellular proteins 
Etk Y40 7.2 1.6 0.01 0.01 FAK 
Enzymatic activation, 
cytoskeletal reorganization, 
altered intracellular location 
CTLA-4 Y201 0.4 2.8 0.01 0.01 jak2, fyn, lck 
Regulates association with 
cellular proteins, altered 
intracellular location 
PXN Y31 3.0 3.7 0.01 0.01 Brk  
Regulates association with 
cellular proteins 
CSK Y184 1.0 1.1 0.01 0.01   
Crk Y221 1.0 1.0 0.01 0.01 Abl 
Regulates cell adhesion and 
interaction with other cellular 
 108 
proteins 
NGFR Y336 0.8 0.9 0.01 0.01   
FRS3 Y416 0.9 0.9 0.01 0.01   
TrkC Y516 0.6 1.0 0.41 0.66   
TrkB Y705/6 0.8 0.3 0.01 0.82   
VEGFR3 Y1265 0.4 0.4 0.01 0.01   
VEGFR3 Y130/1 0.7 0.9 0.98 0.19   
VEGFR2 Y1214 1.0 1.0 0.01 0.01 VEGFR2 Enzymatic activation 
VEGFR1 Y1169 1.3 0.7 0.01 0.11  
Regulates association with 
cellular proteins 
PLCG1 Y783 2.8 5.7 0.01 0.01 Syk, EGFR  
Regulates association with 
cellular proteins, regulates cell 
motility 
PLCG1 Y771 1.0 0.9 0.01 0.01 Syk, EGFR  
PLCG1 Y472 1.5 1.3 0.17 0.05   
PKR T451 0.6 0.2 0.24 0.03 PKR Activation  
FLT3 Y597/9 1.2 0.8 0.01 0.42 FLT3(Y599) 
Regulates association with 
cellular proteins(Y599), 
activation(Y599) 
FLT3 
Y589/9
1 0.9 1.1 0.78 0.14 FLT3(Y589) 
Inhibition(Y589), regulates 
association with cellular 
proteins(Y589), 
activation(Y591) 
gp130 Y814 1.1 1.4 0.02 0.03  
Regulates cell cycle , regulates 
transcription  
gp130 S782 1.1 0.7 0.02 0.01  
Receptor internalization , protein 
degradation 
gp130 Y767 0.4 1.3 0.01 0.04  
Regulates cell cycle , regulates 
transcription  
MEK2 Y216 0.4 0.7 0.11 0.29  Inhibition 
PIK3R1 S607/8 1.1 0.5 0.27 0.05 
InsR (S607), 
PIK3CA 
(S608) Activation(S608) 
Kit S821 1.2 1.4 0.06 0.01 kit Phosphorylation , activation 
Kit Y721 0.9 0.9 0.01 0.01  
Regulates cell growth , regulates 
apoptosis 
RIPK1 
Y384/7
/9 0.2 1.1 0.04 0.83   
ROCK2 
S1133/
4/7 0.9 0.4 0.03 0.63   
IKK-α T23 1.0 1.0 0.01 0.01 Akt2 
Regulate apoptosis, enzymatic 
activation 
mucin 1 
T1227/
9 0.5 0.4 0.19 0.07 
GSK3B 
(T1227), 
Src(T1229) 
Regulates association with 
cellular proteins(T1227/9) 
PDGFRb Y740 0.9 0.9 0.01 0.01 PDGFRb 
Regulates association with 
cellular proteins , activation 
PDGFRb 
Y579/8
1 0.9 0.8 0.01 0.01 
PDGFRb 
(Y579/81) 
Enzymatic activation(Y579/81), 
regulates association with 
cellular proteins (Y579/81)   
CSFR Y809 0.7 0.7 0.01 0.01 CSFR Regulates cell cycle, activation 
CSFR Y561 0.8 0.7 0.01 0.04 CSFR 
Activation, regulates association 
with cellular proteins 
PPP2CA T304 0.7 0.8 0.01 0.01  
Regulates cell growth , 
inhibition 
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PTP1B S50 1.3 1.1 0.01 0.01 CLK1, Akt1 
Enzymatic activation , inhibition 
, regulates association with 
cellular proteins 
Nik T559 1.0 0.9 0.01 0.01   
eNOS S1176 0.9 1.3 0.46 0.71 AMPK1, Akt1 Enzymatic activation, activation 
Grb10 S150 0.4 0.5 0.01 0.01 ERK2, ERK1 Inhibition 
IFNGR1 Y479 0.9 0.6 0.85 0.06   
IFNGR1 Y457 6.3 3.4 0.01 0.01  
Regulates association with 
cellular proteins 
Jun S73 0.9 1.1 0.04 0.01 JNK1  
Jun S63 1.9 1.6 0.01 0.01 JNK1 and JNK2 
STMN1 S62 1.0 1.0 0.01 0.01 PKACa 
Regulates cell cycle, regulates 
apoptosis, cytoskeletal 
reorganization, inhibition, 
regulates association with 
cellular proteins 
STMN1 S15 1.1 0.9 0.01 0.02 
PAK1, 
PKACa, 
CaMK4  
Regulates cell cycle, regulates 
apoptosis , cytoskeletal 
reorganization , inhibition, 
regulates association with 
cellular proteins 
CDK2 T160 0.9 0.6 0.15 0.01 CCRK 
Regulates cell cycle, enzymatic 
activation, activation 
CDK2 
T14/Y1
5 1.0 0.9 0.01 0.01 wee1(Y15) 
Inhibition (T14/Y15), regulates 
cell cycle(Y15) 
Pyk2 Y402 1.0 0.9 0.01 0.01  
Regulates cell cycle, enzymatic 
activation, altered intracellular 
location. Induce interaction with: 
Src  
CDK7 T170 0.7 0.9 0.10 0.01 CDK2, Cdc2 Activation 
cyclin D1 T286/8 1.0 0.9 0.01 0.01 IKK-α(T286) Protein degradation(T286) 
p300 S1834 0.9 1.1 0.01 0.01 Akt1 
Regulates transcription , 
regulates association with 
cellular proteins 
p300 S89 0.6 4.1 0.01 0.36 
PKCA, 
AMPK1, 
PKCD 
Regulates cell growth, 
inhibition, regulates 
transcription, regulates 
association with cellular 
proteins, activation 
CD28 Y206/9 0.7 0.4 0.82 0.37   
HSP70 Y525 1.1 0.4 0.01 0.39  Altered intracellular location 
HSP27 S82/83 0.5 0.9 0.39 0.34 
MAPKAPK2 
(S82), 
Akt1(S82), 
PKD1(S82) 
Activation, altered intracellular 
location, and more(S82/83) 
EphA2 Y772 0.9 1.8 0.28 0.45   
EphA2 Y594 8.6 7.6 0.01 0.01   
EphA2 Y588 0.9 1.3 0.50 0.39   
EphA1 Y781 1.7 1.4 0.08 0.04   
p47phox S370 4.6 3.1 0.01 0.01 
PKCA, 
PKACa 
Enzymatic activation , altered 
intracellular location 
p40phox T154 1.7 0.4 0.01 0.01 PKCA  
WASP Y291 1.2 0.3 0.45 0.05 
Hck, Lyn, Abl, 
Lck, Ack 
Enzymatic activation , regulates 
association with cellular protein 
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Syk Y525/6 0.9 0.5 0.62 0.24 Syk(Y525/6) Enzymatic activation(Y525/6) 
Cot S400 0.6 3.1 0.01 0.19 Akt1 regulates transcription 
CaMK2α T286 1.2 1.5 0.32 0.78 CaMK2-α Enzymatic activation 
smMLC
K S1773 0.9 0.9 0.01 0.01   
MKP-1 S359 0.3 0.7 0.01 0.01  Protein stabilization 
MKP-1 S323 0.3 0.5 0.06 0.32 ERK3 
Regulates association with 
cellular proteins , protein 
degradation 
MKP-1 S296 0.9 1.3 0.40 0.02 ERK2 
Regulates association with 
cellular proteins , protein 
degradation 
PLCB1 S887 1.0 1.1 0.01 0.01 PKCA(rat) Inhibition(rat) 
PLCB1 
T333/4/
6 0.8 1.2 0.01 0.01   
BLNK Y96 0.9 0.9 0.01 0.01 Syk 
Regulates transcription, 
regulates association with 
cellular proteins. 
BLNK Y72 1.0 1.0 0.01 0.01 Syk 
Regulates transcription, 
regulates association with 
cellular proteins. 
DAPP1 Y139 1.1 4.0 0.01 0.01  
Altered intracellular location, 
regulates association with 
cellular proteins, activation. 
RelB S573 1.0 1.5 0.01 0.01   
APE1 S289 1.2 0.8 0.01 0.24   
Tyk2 
Y1054/
5 1.2 0.5 0.10 0.07 
Tyk2 
(Y1054/5) Enzymatic activation(Y1054/5) 
p70S6Kb S473 1.1 0.9 0.02 0.11 
PKCB, PKCA, 
PKCI, PKCG, 
PKCE, PKCZ, 
PKCD altered intracellular location 
CXCR4 Y157 6.1 2.3 0.01 0.01   
Regulates transcription, 
phosphorylation 
CCR5 S336/7 1.7 9.4 0.01 0.01 GRK3(S336/7) receptor internalization(S336/7) 
CCR2 Y139 1.4 1.9 0.01 0.01 jak2 
Regulates association with 
cellular proteins.  
IL7R Y449 1.0 0.8 0.63 0.26  
Regulates association with 
cellular proteins 
IL1A S87 1.2 0.9 0.01 0.01   
IL-16 S143/4 1.2 0.4 0.66 0.06   ERK2(S144), ERK1(S144) 
IL4R Y713 0.7 0.8 0.24 0.03  
Regulates cell growth , regulates 
association with cellular proteins 
IL2RB Y536 0.9 1.0 0.28 0.02 Lck  
IL2RB Y364 0.8 0.9 0.01 0.01  
Regulates association with 
cellular proteins 
IL-10R-
A Y496 0.2 0.7 0.01 0.01   
IKK-β Y199 0.7 0.7 0.27 0.44 Src 
Regulates transcription and 
activation 
IKK-β Y188 0.4 1.1 0.56 0.01 Src 
Regulates transcription and 
activation 
HMGA1 T52 0.8 0.9 0.01 0.01  Regulates apoptosis 
Lef1 S166 1.3 1.0 0.01 0.01   
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Lef1 T155 1.0 1.2 0.01 0.01   
DOCK2 
Y209/2
12 1.0 1.0 0.01 0.01   
CBP S2063 1.0 1.0 0.01 0.01   
DNA-PK T2638 1.0 0.7 0.07 0.11 
ATM , DNA-
pk Enzymatic inhibition 
DNA-PK T2609 1.3 1.1 0.01 0.01 
ATM , DNA-
pk enzymatic inhibition 
PKR T446 1.4 0.7 0.01 0.71 PKR 
Regulates cell growth, regulates 
cell cycle, enzymatic activation, 
activation  
Btk Y550 2.7 1.1 0.54 0.10 syk, lyn, btk Activation 
Btk Y222 1.0 1.8 0.01 0.01 syk, lyn, btk Activation 
ITK Y512 0.8 0.4 0.01 0.01 Lck Activation 
FAK Y397 2.9 2.5 0.14 0.01 FAK 
Regulates apoptosis, cytoskeletal 
reorganization, altered 
intracellular location, regulates 
cell adhesion, regulates 
association with cellular proteins 
, protein degradation, activation 
TAK1 S192 15.0 22.9 0.15 0.09 TAK1 Activation 
TAK1 T184 1.3 1.0 0.01 0.01 TAB1 Activation 
PKACa S338 3.9 2.5 0.02 0.02   
PKACa T195/7 7.7 1.9 0.02 0.01   
Akt3 T447 1.0 1.0 0.01 0.01   
Akt3 S120 1.4 1.2 0.82 0.74   
Akt1 Y326 0.5 1.3 0.01 0.06 Src 
Regulates apoptosis, 
transcription. Activation 
Akt1 S129 1.1 0.5 0.60 0.25 CK2-A1 Enzymatic activation 
ERK3 S189 1.3 2.1 0.05 0.21 ERK3  
ERK2 Y204 1.2 1.0 0.01 0.01 MEK1  
ERK1 T202/4 1.0 1.1 0.01 0.01 
Cot(T202/4), 
MEK1/2 
(T202/4), 
Lck(T204), 
ERK1(T204) 
 Activation (T202/4), enzymatic 
activation (T202/4) 
TBK1 S172 1.0 1.1 0.01 0.01  Enzymatic activation 
Jak3 Y981 1.0 3.5 0.01 0.01 Jak3  Enzymatic inhibition 
Jak2 
Y1007/
8 1.5 2.0 0.78 0.04 Jak2 Activation(Y1007/8) 
Jak1 
Y1022/
3 0.3 0.6 0.01 0.01 Jak3 (Y1022/3) 
JNK1 S377 1.1 1.2 0.01 0.01   
p38-α Y323 1.2 1.0 0.01 0.01 
Fyn, Lck, 
ZAP70 
Enzymatic activation,  
phosphorylation 
p38-α 
T179/Y
181 1.3 1.4 0.88 0.76 
MKK3/6(T179
/Y181) 
Activation, Enzymatic 
activation, and more 
(T179/Y181) 
axin-1 S486 3.9 3.8 0.02 0.01 
GSK3B 
(mouse) Activation(mouse) 
Notch 2 S2070 1.3 1.6 0.01 0.01   
Notch 2 T1808 0.8 1.0 0.02 0.01   
GSK3-β Y216 1.1 1.0 0.01 0.01 MEK1, GSK3B 
GSK3-β S9 0.8 0.6 0.01 0.14 PKACa Regulates apoptosis, inhibition, 
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regulates cell adhesion, 
enzymatic inhibition 
Elk-1 T417 0.9 0.9 0.01 0.01 PRP4 transcription 
Elk-1 S389 1.2 1.2 0.01 0.01 ERK1 
Activation, regulates 
transcription 
Fos T232 0.2 0.2 0.05 0.01 ERK5, ERK2 
Altered intracellular location , 
activation  
Casp8 S347 3.4 2.8 0.01 0.01 p38-α Regulates apoptosis, inhibition 
Casp3 S150 1.2 1.0 0.01 0.01 p38-α Regulates apoptosis, inhibition 
IRAK-1 S568 0.2 0.2 0.01 0.01   
IRAK-1 T387 1.0 1.1 0.01 0.01   
IRAK-1 S376 1.1 7.3 0.01 0.22 IRAK-4 
Activation and results after 
phosphorylation of T209 
IRAK-1 T209 3.2 3.7 0.01 0.01 IRAK-1 
Required for S376 
phosphorylation 
IRAK-1 T100 1.3 1.2 0.01 0.01 Akt1 regulates transcription 
FADD S194 10.6 5.9 0.08 0.01 
CK1-A, 
MEKK1, 
MKK7 
Altered intracellular location, 
regulates apoptosis, regulates 
cell cycle 
HIF2A T840 1.0 1.0 0.01 0.01  
Regulates transcription, 
activation(mouse) 
HIF1A T796 3.0 9.2 0.01 0.01   
XIAP S87 0.9 0.8 0.03 0.18 Akt2, Akt1 
Regulates apoptosis , protein 
stabilization 
BATF T48 1.0 2.0 0.01 0.01   
NFAT4 S163/5 0.2 0.5 0.01 0.01 JNK2(S163/5) 
Altered intracellular 
location(S163/5), regulates 
transcription(S163/5) 
NFAT2 S294 2.4 1.9 0.01 0.01 PKACa 
Inhibition , altered intracellular 
location 
NFAT2 S245 0.9 1.1 0.01 0.01 PKACa 
Inhibition , altered intracellular 
location 
NFAT1 S326 0.9 0.8 0.01 0.01   
NFAT1 S168 0.9 0.8 0.01 0.01   
Smad4 T277 1.6 1.0 0.01 0.01   
Smad3 
S422/3/
5 11.3 8.2 0.01 0.01  
Regulates 
transcription(S422/3/5) 
Smad3 S208 2.8 4.2 0.22 0.38 ERK2  
Inhibition , altered intracellular 
location , regulates transcription 
Smad2 S255 1.2 1.1 0.88 0.75 ERK2, ERK1 
Regulates transcription, protein 
stabilization, regulates 
association with cellular 
proteins, activation. Induce 
interaction with: Smad4  
Smad2 T8 2.9 1.4 0.01 0.01 ERK1 
Regulates transcription , protein 
stabilization , regulates 
association with cellular proteins 
, activation  .Induce interaction 
with:Smad4  
Smad1 
S462/3/
5 7.5 1.0 0.01 0.01 
BMPR1B 
(S462/3/5) 
Activation, altered intracellular 
location, and more(S462/3/5) 
ATF-4 S245 1.0 0.8 0.01 0.01 RSK2 activation, regulates cell growth 
ATF-2 T51/3/5 0.7 1.0 0.29 0.01 
VRK1(T55), 
p38-α(T51/3), 
JNK1(T51/3) 
Regulates transcription(T55), 
protein stabilization (T51/3/5), 
activation(T55) 
